0001571049-16-019407.txt : 20161103 0001571049-16-019407.hdr.sgml : 20161103 20161103161134 ACCESSION NUMBER: 0001571049-16-019407 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161103 DATE AS OF CHANGE: 20161103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Semler Scientific, Inc. CENTRAL INDEX KEY: 0001554859 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 261367393 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36305 FILM NUMBER: 161971706 BUSINESS ADDRESS: STREET 1: 2330 N.W. EVERETT STREET CITY: PORTLAND STATE: OR ZIP: 97210 BUSINESS PHONE: 408-627-4557 MAIL ADDRESS: STREET 1: 2330 N.W. EVERETT STREET CITY: PORTLAND STATE: OR ZIP: 97210 10-Q 1 t1602555_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2016

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from ___ to ___

Commission File Number 001-36305

SEMLER SCIENTIFIC, INC.

(Exact name of Registrant as specified in its Charter)

Delaware	26-1367393
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification Number)

2330 N.W. Everett
Portland, Oregon	97210
(Address of principal executive offices)	(Zip Code)

Registrant's Telephone Number, Including Area Code: (877) 774-4211

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer	¨	Accelerated Filer	¨

Non-Accelerated Filer	¨	Smaller Reporting Company	x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of October 28, 2016, there were 5,123,568 shares of the issuer’s common stock, $0.001 par value per share, outstanding.

TABLE OF CONTENTS

		Page
Part I.	Financial Information		1

Item 1.	Financial Statements		1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		11
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		16
Item 4.	Controls and Procedures		16

Part II.	Other Information		18

Item 1.	Legal Proceedings		18
Item 1A.	Risk Factors		18
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		18
Item 3.	Defaults upon Senior Securities		18
Item 4.	Mine Safety Disclosures		18
Item 5.	Other Information		18
Item 6.	Exhibits		18

Signatures			19

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements.

In some cases, you can identify forward-looking statements by terminology, such as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “believes,” “seeks,” “may,” “should,” “continue,” “could” or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this report.

You should read this quarterly report and the documents that we reference herein and therein and have filed as exhibits to this report, completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this quarterly report is accurate as of the date of this report only. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. These risks and uncertainties, along with others, are described above under the heading “Risk Factors” in our annual report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 26, 2016. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this quarterly report, and particularly our forward-looking statements, by these cautionary statements.

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Semler Scientific, Inc.

Condensed Statements of Operations

(In thousands, except share and per share amounts)

	(Unaudited)						(Unaudited)

	For the three months ended September 30						For the nine months ended September 30
	2016			2015			2016			2015

Revenue	$	1,982		$	1,562		$	5,118		$	4,067

Operating expenses:
Cost of revenue		398			385			1,348			887
Engineering and product development		183			268			634			983
Sales and marketing		950			1,314			2,952			3,809
General and administrative		706			1,147			2,236			2,602
Total operating expenses		2,237			3,114			7,170			8,281

Loss from operations		(255	)		(1,552	)		(2,052	)		(4,214	)

Other expense		(107	)		(28	)		(282	)		(79	)

Net loss	$	(362	)	$	(1,580	)	$	(2,334	)	$	(4,293	)

Net loss per share, basic and diluted	$	(0.07	)	$	(0.32	)	$	(0.46	)	$	(0.87	)

Weighted average number of shares used in computing basic and diluted loss per share		5,123,568			4,983,198			5,123,568			4,909,354

See accompanying notes to unaudited condensed financial statements.

Table of Contents

Semler Scientific, Inc.

Condensed Balance Sheets

(In thousands, except share and per share amounts)

	*(Unaudited)* September 30,			December 31,
	2016			2015

Assets

Current assets:
Cash	$	517		$	405
Trade accounts receivable, net of allowance for doubtful accounts of $76 and $183, respectively		897			1,278
Prepaid expenses and other current assets		134			69
Total current assets		1,548			1,752

Assets for lease, net		853			830
Property and equipment, net		544			497
Long-term deposits		15			-
Total assets	$	2,960		$	3,079

Liabilities and Stockholders' Deficit

Current liabilities:
Accounts payable	$	281		$	839
Accrued expenses		2,297			2,317
Loans payable		72			-
Deferred revenue		667			952
Total current liabilities		3,317			4,108

Long-term liabilities:

Deferred rent		55			43
Accrued interest expense		138			-
Related party loan payable net of debt discount of $164 and $0, respectively		1,336			-
Loan payable net of debt discount of $80 and $0, respectively		920			-

Total long-term liabilities		2,449			43

Stockholders' deficit:
Common stock, $0.001 par value; 50,000,000 shares authorized; 5,148,568 and 5,148,568 shares issued, and 5,123,568 and 5,123,568 outstanding (net of treasury shares of 25,000 and 25,000), respectively		5			5
Additional paid-in capital		21,891			21,291
Accumulated deficit		(24,702	)		(22,368	)

Total stockholders' deficit		(2,806	)		(1,072	)

Total liabilities and stockholders' deficit	$	2,960		$	3,079

See accompanying notes to unaudited condensed financial statements.

Table of Contents

Semler Scientific, Inc.

Condensed Statements of Cash Flows

(In thousands)

	*(Unaudited)* Nine months ended September 30
	2016			2015

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(2,334	)	$	(4,293	)

Reconciliation of Net Loss to Net Cash Used in Operating Activities:
Amortization of debt discount		133			55
Depreciation		336			211
Loss on disposal of assets for lease		149			106
Allowance for doubtful accounts		66			119
Stock-based compensation expense		222			549
Changes in Operating Assets and Liabilities:
Trade accounts receivable		315			(203	)
Prepaid expenses and other current assets		(80	)		40
Accounts payable		(558	)		(28	)
Accrued expenses		130			237
Deferred revenue		(285	)		716
Net Cash Used in Operating Activities		(1,906	)		(2,491	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment		(140	)		(195	)
Change in restricted cash		-			2,100
Purchase of assets for lease		(415	)		(484	)
Net Cash (Used in) Provided by Investing Activities		(555	)		1,421

CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock		-			999
Stock options exercised		-			14
Offering costs		-			(174	)
Proceeds from loans payable		2,590			-
Payments of loans payable		(17	)		(2,000	)
Net Cash Provided by (Used in) Financing Activities		2,573			(1,161	)

INCREASE (DECREASE) IN CASH		112			(2,231	)
CASH, BEGINNING OF PERIOD		405			4,156

CASH, END OF PERIOD	$	517		$	1,925
Cash paid for interest	$	3		$	19
Supplemental disclosure of noncash financing activity:
Fair value of warrants issued to lenders	$	322		$	-

See accompanying notes to unaudited condensed financial statements

Table of Contents

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

Basis of Presentation

Semler Scientific, Inc., a Delaware corporation (“Semler” or “the Company”), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K filed with the SEC on February 26, 2016 (the “Annual Report”). The balance sheet as of December 31, 2015 included in this report has been derived from the audited financial statements included in the Annual Report. In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year. Items in prior period financial statements have been adjusted to conform with the current period presentation.

Going Concern

The Company has incurred recurring losses since inception and expects to continue to incur losses as a result of costs and expenses related to the Company’s marketing and other promotional activities, research and continued development of its products. As of September 30, 2016, the Company has negative working capital of $1,769, cash of $517 and stockholders’ deficit of $2,806. The Company’s principal sources of cash have included the issuance of equity securities, borrowings under loan agreements, revenue from leasing its product and providing testing services. To increase revenue, the Company’s operating expenses will continue to grow and, as a result, the Company will need to generate significant additional revenue to achieve profitability.

The Company’s financial statements as of and for the three and nine months ended September 30, 2016 have been prepared under the assumption that the Company will continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to generate additional revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company can give no assurances that additional capital that the Company is able to obtain, if any, will be sufficient to meet the Company’s needs. If the Company is unable to raise additional capital or increase revenue from leasing its product and providing testing services within the next twelve months to continue to fund operations at its current cash expenditure levels, the Company’s operations will need to be curtailed. The foregoing conditions raise substantial doubt about the Company’s ability to continue as a going concern.

Assets for Lease, net

Assets for lease consist of the following:

	September 30, 2016			December 31, 2015

Assets for lease	$	1,338		$	1,280
Less: Accumulated depreciation		(485	)		(450	)
Assets for lease, net	$	853		$	830

Depreciation expense amounted to $81 and $72 for the three months ended September 30, 2016 and September 30, 2015, respectively. Depreciation expense amounted to $243 and $195 for the nine months ended September 30, 2016 and September 30, 2015, respectively. Reduction to accumulated depreciation for returned items was $91 and $34 for the three months ended September 30, 2016 and September 30, 2015, respectively. Reduction to accumulated depreciation for returned items was $208 and $75 for the nine months ended September 30, 2016 and September 30, 2015, respectively.

Table of Contents

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

Property and Equipment, net

Property and equipment, net consists of the following:

	September 30, 2016			December 31, 2015

Property and equipment	$	681		$	542
Less: accumulated depreciation		(137	)		(45	)
Property and equipment, net	$	544		$	497

Depreciation expense amounted to $33 and $10 for the three months ended September 30, 2016 and 2015, respectively. Depreciation expense amounted to $92 and $16 for the nine months ended September 30, 2016 and 2015, respectively.

Accrued Expenses

Accrued expenses consist of the following:

	September 30, 2016		December 31, 2015

Offering Costs	$	227	$	227
Compensation		1,443		1,093
Miscellaneous Accruals		627		997
Total Accrued Expenses	$	2,297	$	2,317

The accumulated offering costs that were accrued pertain to consulting fees associated with securing equity financing for the Company prior to the initial public offering. Prior to becoming Chief Executive Officer (“CEO”), the Company’s current CEO performed consulting services for the Company, which included managing finance, sales, marketing, operational and strategic planning for the Company, as well as assistance and strategic guidance in securing financing. The Company has agreed to a payment date of December 31, 2016 for these fees.

Commitments and Contingencies

Facilities Leases

Facilities lease expense recognized by the Company was $16 and $93 for the three months ended September 30, 2016 and 2015, respectively. Facilities lease expense recognized by the Company was $53 and $194 for the nine months ended September 30, 2016 and 2015, respectively.

On September 23, 2014, the Company entered into a 36-month lease agreement for office space for the sales and marketing team located in Menlo Park, CA. The lease term commenced February 1, 2015 and is effective through January 31, 2018. Payments required under the terms of the lease are $17.0 per month from February 2015 to January 2016, $17.5 per month from February 2016 to January 2017, and $18.0 per month from February 2017 to January 2018. The Company anticipates total future lease payments of $52.4 for the year ended December 31, 2016; $215.4 for the year ended December 31, 2017; and $18.0 for the year ended December 31, 2018. On July 15, 2015, the Company entered into a 30-month sublease agreement for the Menlo Park office space, which commenced August 1, 2015 and is effective through the term of the lease, January 31, 2018. Payments required to the Company under the terms of the sublease are $15.5 per month from August 2015 to July 2016, $16.0 per month from August 2016 to July 2017, and $16.5 per month from August 2017 to January 2018. The Company anticipates receipt of total future sublease payments of $48.0 for the year ended December 31, 2016; $194.4 for the year ended December 31, 2017; and $16.5 for the year ended December 31, 2018. The Company recorded an expense of $50, which represented the difference between estimated cash payments on the lease and cash receipts from the sublease. The Company recorded the resulting long-term liability as deferred rent on the Company’s balance sheet. The cease use date is July 31, 2015.

Table of Contents

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

Loans Payable

Loans from Related Parties

On January 15, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $1,000 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $1,000 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

On January 21, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $500 unsecured loan for a 24-month term at a fixed interest rate of 5% per annum. Under the loan agreement, the Company will pay $500 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

Other Loans

On March 31, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $700 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $700 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 79,459 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

On April 5, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $160 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $160 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 18,162 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

Table of Contents

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

The Company uses the Black-Scholes pricing model to determine the relative fair market value of warrants. The relative fair market value of each warrant is estimated on the date of grant. There were no warrants issued during the three months ended September 30, 2016 or 2015. The relative fair value of the warrants granted is estimated on the date of grant using the Black-Scholes pricing model and the following assumptions for the periods presented:

	Nine months ended September 30,
	2016			2015
Expected term (in years)		2			-
Risk-free interest rate		0.73 – 0.89	%		-
Expected volatility		97.7 – 99.0	%		-
Expected dividend rate		0	%		-

The assumptions are based on the following for each of the years presented:

Valuation Method — The Company estimates the relative fair value of warrants using the Black-Scholes pricing model.

Expected Term — The Company uses the amount of time the warrants are exercisable per the contractual terms of the award.

Volatility — Because the Company has limited trading history by which to determine the volatility of its own common stock price, the expected volatility being used is derived from the historical stock volatilities of a representative industry peer group of comparable publicly listed companies over a period approximately equal to the expected term of the warrants.

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the warrants.

Expected Dividend — The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.

On July 1, 2016, the Company entered into a software license financing agreement with Ascentium Capital, LLC. Pursuant to the agreement, the Company obtained a $39 loan for a 12-month term at a fixed interest rate of 8.9% per annum. to finance its upfront software licensing fee. The Company has no obligation to make any payments during the first three months, and agreed to pay $4.6 of principal and accrued interest for each of the last 9 months of the term. The loan may be prepaid at any time prior to maturity without penalty. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan.

On July 8, 2016, the Company entered into an additional software license financing agreement with Ascentium Capital, LLC. Pursuant to the agreement, the Company obtained a $74 loan for a 36-month term at a fixed interest rate of 8.9% per annum. Under the loan agreement, the Company agreed to make monthly payments of $2.4 of principal and accrued interest. The loan may be prepaid at any time prior to maturity without penalty. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan.

On July 11, 2016, the Company entered into a secured equipment financing agreement with Royal Bank America Leasing, L.P. Pursuant to the agreement, the Company obtained a $150 loan for a 36-month term at a fixed interest rate of 9.3% per annum, which is secured by related equipment. The loan is to be disbursed in three installments. The first installment was for $37. The second installment for $52 will be disbursed in July 2017, and the third installment for $61 will be disbursed in July 2018. Under the loan agreement, the Company will pay $3.5 of principal and accrued interest for each of the first 12 months, $4.4 of principal and accrued interest for each of months 13-24, and $5.3 of principal and accrued interest for each of months 25-36. The loan may be prepaid at any time only in accordance with the agreement. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan.

Table of Contents

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

For the three months ended September 30, 2016 and 2015 interest expense was $105 and $25, respectively. Of this total interest expense, the portion related to amortization of debt discount was $50 and $18, respectively. For the nine months ended September 30, 2016 and 2015 interest expense was $275 and $74, respectively. Of this total interest expense, the portion related to amortization of debt discount was $133 and $55, respectively.

Indemnification Obligations

The Company enters into agreements with customers, partners, lenders, consultants, lessors, contractors, sales representatives and parties to certain transactions in the ordinary course of the Company’s business. These agreements may require the Company to indemnify the other party against third party claims alleging that its product infringes a patent or copyright. Certain of these agreements require the Company to indemnify the other party against losses arising from: a breach of representations or covenants, claims relating to property damage, personal injury or acts or omissions of the Company, its employees, agents or representatives. The Company has also agreed to indemnify the directors and certain of the officers and employees in accordance with the by-laws of the Company. These indemnification provisions will vary based upon the nature and terms of the agreements. In many cases, these indemnification provisions do not contain limits on the Company’s liability, and the occurrence of contingent events that will trigger payment under these indemnities is difficult to predict. As a result, the Company cannot estimate its potential liability under these indemnities. The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company had not made any significant payment under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. In certain cases, the Company has recourse against third parties with respect to the aforesaid indemnities, and the Company believes it maintains adequate levels of insurance coverage to protect the Company with respect to potential claims arising from such agreements.

Net Loss Per Common Share

Because the Company was in a loss position for each of the periods presented, diluted net loss per share is the same as basic net loss per share for each period as the inclusion of all potential common shares outstanding would have been anti-dilutive. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been anti-dilutive:

	Three months ended September 30,				Nine months ended September 30,
	2016		2015		2016		2015
Weighted average shares outstanding:
Common stock warrants		722,988		359,714		671,516		359,714
Options		2,069,517		852,040		2,041,515		768,236
Total		2,792,505		1,211,754		2,713,031		1,127,950

Stock Option Plan

The Company’s stock-based compensation program is designed to attract and retain employees while also aligning employees' interests with the interests of its stockholders. Stock options have been granted to employees under the stockholder-approved 2007 Key Person Stock Option Plan (“2007 Plan”) or the stockholder-approved 2014 Stock Incentive Plan (“2014 Plan”). Stockholder approval of the 2014 Plan became effective in September 2014. The 2014 Plan originally provided that the aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2014 Plan may not exceed 450,000 shares (the “Share Reserve”), however in October 2015, the stockholders approved a 1,500,000 increase to the Share Reserve. In addition, the Share Reserve automatically increases on January 1st of each year, for a period of not more than 10 years, beginning on January 1st of the year following the year in which the 2014 Plan became effective and ending on (and including) January 1, 2024, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Company’s Board of Directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise occur. On January 1, 2015, the Share Reserve increased by 188,640 shares due to the automatic 4% increase. On January 1, 2016, the Share Reserve increased by

Table of Contents

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

204,943 shares due to the automatic 4% increase. The Share Reserve is currently 2,343,583 shares for the year ending December 31, 2016.

In light of stockholder approval of the 2014 Plan, the Company no longer grants equity awards under the 2007 Plan. As of September 30, 2016, 0 shares of an aggregate total of 407,500 shares were available for future stock-based compensation grants under the 2007 Plan and 666,121 shares of an aggregate total of 2,343,583 shares were available for future stock-based compensation grants under the 2014 Plan.

Aggregate intrinsic value represents the difference between the closing market value as of September 30, 2016 of the underlying common stock and the exercise price of outstanding, in-the-money options. A summary of the Company’s stock option activity and related information for the nine months ended September 30, 2016 is as follows:

	Options Outstanding
	Number of Stock Options Outstanding		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)		Aggregate Intrinsic Value (in thousands)
Balance, January 1, 2016		1,909,911	$	2.58		8.56	$	813
Options granted		160,000		2.23
Options exercised		-		-
Options forfeited/canceled		394		3.44
Balance, September 30, 2016		2,069,517	$	2.58		7.93	$	389
Exercisable as of September 30, 2016		1,670,236	$	2.60		7.74	$	389

The total compensation cost related to unvested stock option awards not yet recognized was $639 as of September 30, 2016. The weighted average period over which the total unrecognized compensation cost related to these unvested stock awards will be recognized is 2.27 years. The estimated fair value of option shares vested during the quarters ended September 30, 2016 and 2015 was $87 and $485, respectively. The estimated fair value of option shares vested during the nine months ended September 30, 2016 and 2015 was $222 and $549, respectively. The weighted average fair value of options granted during the quarter ended September 30, 2015 was $2.26 per share, or an aggregate grant date fair value of $1,965. There were no options granted during the quarter ended September 30, 2016. The weighted average fair value of options granted during the nine months ended September 30, 2016 and 2015 was $1.43 per share and $2.17 per share, respectively, or an aggregate grant date fair value of $229 and $2,161, respectively.

On February 18, 2016 the Compensation Committee of the Company’s Board of Directors granted, and the full Board ratified, an option to acquire an aggregate of 125,000 shares under the 2014 Plan to the Company’s CEO. This option vests 25% on the one-year anniversary of the grant date and monthly thereafter for 36 months, such that the option is vested in full on the four-year anniversary of the grant date. On February 18, 2016 the Company’s Compensation Committee granted, and the full Board ratified, options to each of the then-seated non-employee Directors to acquire 5,000 shares, for an aggregate of 35,000 shares, under the 2014 Plan. These options vest on the one-year anniversary of their grant date.

Determining the Fair Value of Stock Options

The Company uses the Black-Scholes pricing model to determine the fair value of stock options. The fair value of each option grant is estimated on the date of the grant. The following assumptions for the periods presented were:

	Three months ended September 30,					Nine months ended September 30,
	2016		2015			2016			2015
Expected term (in years)		-		5			5			5
Risk-free interest rate		-		1.5 – 1.7	%		1.21	%		1.5 – 1.7	%
Expected volatility		-		83.0	%		80.4	%		82.9	%
Expected dividend rate		-		0	%		0	%		0	%

Table of Contents

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

The assumptions are based on the following for each of the years presented:

Valuation Method — The Company estimates the fair value of its stock options using the Black-Scholes option pricing model.

Expected Term — The Company estimates the expected term consistent with the simplified method identified by the SEC. The Company elected to use the simplified method because of its limited history of stock option exercise activity and its stock options meet the criteria of the “plain-vanilla” options as defined by the SEC. The simplified method calculates the expected term as the average of the vesting and contractual terms of the award.

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the options.

Forfeiture — The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and records stock-based compensation expense only for those awards that are expected to vest. All stock-based payment awards are amortized on a straight-line basis over the requisite service periods of the awards, which are generally the vesting periods. If the Company’s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.

The Company has recorded an expense of $87 and $485 as it relates to stock-based compensation for the three months ended September 30, 2016 and 2015, respectively. The Company has recorded an expense of $222 and $549 as it relates to stock-based compensation for the nine months ended September 30, 2016 and 2015, respectively, which was allocated as follows based on the role and responsibility of the recipient in the Company:

	Three months ended September 30,				Nine months ended September 30
	2016		2015		2016		2015
Cost of Revenue	$	1	$	1	$	1	$	2
Engineering and Product Development		16		9		34		15
Sales and Marketing		27		77		70		102
General and Administrative		43		398		117		430
Total	$	87	$	485	$	222	$	549

Subsequent Events

None.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read together with our condensed unaudited financial statements and the related notes appearing elsewhere in this quarterly report on Form 10-Q and with the audited financial statements and notes for the fiscal year ended December 31, 2015, and the information under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed with the SEC on February 26, 2016, or the Annual Report. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements” for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under “Risk Factors” in our Annual Report.

Overview

We are an emerging growth company that provides technology and software solutions to improve the clinical effectiveness of healthcare insurers and physician groups. Our mission is to develop, manufacture and market innovative proprietary products and services that assist our customers in evaluating and treating chronic diseases. In 2011, we began commercializing our first patented and U.S. Food and Drug Administration, or FDA, cleared product, which measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease, or PAD, which is associated with higher risk of heart attacks and strokes. In March 2015, we received FDA 510(k) clearance for the next generation version of our product, QuantaFlo™, which we began commercializing in August 2015. In April 2015, we launched our multi-test service platform, WellChec™, to more comprehensively evaluate our customers’ patients for chronic disease, including heart attacks and strokes. However, in October 2016, we shifted our marketing focus for WellChec™ from direct contracts with health insurance plans under which we acted as the primary WellChec™ service provider to contracts to supply our software and equipment to vendors who employ medical professionals to do annual wellness visits for health insurance plans. We believe our products position us to provide valuable information to our customer base of insurance plans, physicians and risk assessment companies, which in turn permit them to better guide patient care.

In the three months ended September 30, 2016 we had total revenue of $1,982,000 and a net loss of $362,000 compared to total revenue of $1,562,000 and a net loss of $1,580,000 in the same period in 2015. In the nine months ended September 30, 2016 we had total revenue of $5,118,000 and a net loss of $2,334,000 compared to total revenue of $4,067,000 and a net loss of $4,293,000 in the same period in 2015.

Emerging Growth Company Elections

The JOBS Act provides that an emerging growth company, such as our company, can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to avail ourselves of this exemption. As a result, our financial statements may not be comparable to other public companies that comply with public company effective dates. In the future, we may elect to opt out of the extended period for adopting new accounting standards. If we do so, we would need to disclose such decision and it would be irrevocable.

Factors Affecting Future Results

We have not identified any factors that have a recurring effect that are necessary to understand period to period comparisons as appropriate, nor any one-time events that have an effect on the financials. We launched our WellChec™ testing services platform in 2015, which significantly impacted revenue growth and expenses in the fourth quarter of 2015. We currently do not anticipate providing WellChec™ testing services as a primary vendor, but will rather focus on supplying our cardiovascular testing products to other risk assessment service providers.

Results of Operations

Three Months Ended September 30, 2016 Compared to Three Months Ended September 30, 2015

Revenue

We had revenue of $1,982,000 for the three months ended September 30, 2016, an increase of $420,000, or 27%, compared to $1,562,000 in the same period in 2015. Our revenue is primarily generated from per-use fees or leasing of our vascular testing systems. For licenses, we recognize revenue monthly for each unit installed with a customer. The average amount recognized each month per unit of product in the field is affected by the mix of units rented by direct customers or distributors, by price changes and by discounts. The primary reason for the increase in revenue was that the total number of installed units in the field generating monthly

Table of Contents

revenue grew 16%, and the average amount of revenue recognized per unit increased 17% as compared to 2015. We believe that growth in the number of monthly invoices is predominately due to our sales and marketing efforts, which added new customers to an established customer base. Change in the average amount of revenue recognized per unit was due to changes in the mix of customers renting units and the migration to QuantaFlo™ from its lower-priced, predecessor product. We recognized $94,000 of revenue from per-use fees, testing services and other sales during the three months ended September 30, 2016, an increase of $38,000, compared to $56,000 in the same period in 2015. We did not recognize any revenue from WellChec™ during the three months ended September 30, 2016, compared to $104,000 in the same period in 2015.

Operating expenses

We had total operating expenses of $2,237,000 for the three months ended September 30, 2016, a decrease of $877,000, or 28%, compared to $3,114,000 in the same period in 2015. The primary reasons for the decrease were decreased general and administrative expense, sales and marketing expense, and engineering and product development expense, partially offset by an increase in cost of revenue. The changes in the various components of our operating expenses are described below.

Cost of revenue

We had cost of revenue of $398,000 for the three months ended September 30, 2016, an increase of $13,000, or 3%, from $385,000 for the same period in the previous year. The primary reasons for the change were an increase of $38,000 associated with employees who oversee manufacturing and fulfillment operations, an increase of $25,000 in depreciation of other capital assets, an increase of $9,000, or 13%, in aggregate depreciation of our vascular testing systems for lease, which corresponds to an increase in the number of installed units in the field generating monthly depreciation charges of 18% and a decrease in average depreciation per unit per month of 5%, and an increase of $3,000 of WellChec™ event expenses. Partially offsetting these changes were lower cost of units that were retired of $48,000 and a decrease in building lease, freight and other miscellaneous items of $14,000.

Engineering and product development expense

We had engineering and product development expense of $183,000 for the three months ended September 30, 2016, a decrease of $85,000, or 32%, compared to $268,000 in the same period in 2015. The decrease was primarily due to lower salary expense of $92,000, lower other expenses of $7,000, and lower clinical study expense of $6,000, which were partially offset by higher consulting costs for new product development of $12,000 and an increase in stock-based compensation expense of $8,000.

Sales and marketing expense

We had sales and marketing expense of $950,000 for the three months ended September 30, 2016, a decrease of $364,000, or 28%, compared to $1,314,000 in the same period in 2015. The decrease was primarily due to lower travel expense of $105,000, lower facility expense of $81,000, lower stock-based compensation expense of $50,000, lower trade show expense of $25,000, lower other expenses of $19,000, and lower salary expense of $9,000 as compared to the same period in 2015. We also had lower sales commissions of $74,000. However, during the three months ended September 30, 2016, we reclassified $103,000 of previously recorded commission expense as a reduction to the commission accrual because such previously recorded amounts were advances against future commissions to be earned by a sales representative.

General and administrative expense

We had general and administrative expense of $706,000 for the three months ended September 30 2016, a decrease of $441,000, or 38%, compared to $1,147,000 in the same period in 2015. The change was primarily due to lower costs associated with stock-based compensation expense of $356,000, lower patent and legal expenses of $74,000, lower taxes and associated expense of $40,000, lower salaries and fees for employees, directors, and consultants of $39,000, lower technical support costs of $11,000, and lower insurance premium fees of $5,000, which changes were partially offset by higher costs for merchant fees and other expenses of $42,000, higher professional fees of $39,000, higher expense for uncollectable accounts of $2,000, and higher travel expenses of $1,000.

Other expense

We had other expense of $107,000 for the three months ended September 30, 2016, an increase of $79,000, or 282%, compared to $28,000 in the same period in 2015. The increase was primarily due to higher interest expense of $80,000 associated with the issuance of promissory notes to lenders, including amortization of debt discount and interest on equipment financing agreements.

Table of Contents

Net loss

For the foregoing reasons, we had a net loss of $362,000, or $0.07 per share, for the three months ended September 30, 2016, a decrease of $1,218,000, or 77%, compared to a net loss of $1,580,000, or $0.32 per share, for the same period in 2015.

Nine Months Ended September 30, 2016 Compared to Nine Months Ended September 30, 2015

Revenue

We had revenue of $5,118,000 for the nine months ended September 30, 2016, an increase of $1,051,000, or 26%, compared to $4,067,000 in the same period in 2015. Our revenue is primarily generated from per-use fees or leasing of our vascular testing systems. For licenses, we recognize revenue monthly for each unit installed with a customer. The average amount recognized each month per unit of product in the field is affected by the mix of units rented by direct customers or distributors, by price changes and by discounts. The primary reason for the increase in revenue was that the total number of installed units in the field generating monthly revenue grew 21%, and the average amount of revenue recognized per unit increased 12% as compared to 2015. We believe that growth in the number of monthly invoices is predominately due to our sales and marketing efforts, which added new customers to an established customer base. Change in the average amount of revenue recognized per unit was due to changes in the mix of customers renting units and the migration to QuantaFlo™ from its lower-priced, predecessor product. We recognized $181,000 of revenue from per-use fees, testing services and other sales during the nine months ended September 30, 2016, an increase of $116,000, compared to $65,000 in the same period in 2015. There was a reduction in revenue of $162,000 for WellChec™ testing services in the nine months ended September 30, 2016, partially as an incentive to a customer to renew and expand an order for additional WellChec™ services from us. We recognized $248,000 of revenue from providing testing services through our WellChec™ platform during the nine months ended September 30, 2015.

Operating expenses

We had total operating expenses of $7,170,000 for the nine months ended September 30, 2016, a decrease of $1,111,000, or 13%, compared to $8,281,000 in the same period in 2015. The primary reasons for the change were decreased sales and marketing expense, general and administrative expense, and engineering and product development expense, partially offset by an increase in cost of revenue. The changes in the various components of our operating expenses are described below.

Cost of revenue

We had cost of revenue of $1,348,000 for the nine months ended September 30, 2016, an increase of $461,000, or 52%, from $887,000 for the same period in the previous year. The primary reasons for the increase were an increase of $133,000 associated with employees who oversee manufacturing and fulfillment operations in connection with the growth in the number of units installed. In addition, we had $80,000 more WellChec™ event expenses, and we had $43,000 increase in cost of units retired as we migrate customers to our QuantaFlo™ product. A portion of the increase is also due to the fact that aggregate depreciation of our vascular testing systems for lease increased $48,000, or 24%, which corresponds to the 24% increase in the number of installed units in the field generating monthly depreciation charges and an increase in average depreciation per unit per month of less than 1%. Other cost of revenue items, such as building lease, freight and other miscellaneous items were $80,000 higher, and depreciation of other capital assets was $77,000 higher in the first nine months of 2016 compared to the same period in 2015.

Engineering and product development expense

We had engineering and product development expense of $634,000 for the nine months ended September 30, 2016, a decrease of $349,000, or 36%, compared to $983,000 in the same period in 2015. The change was primarily due to decreased salary expense of $122,000, lower clinical study expense of $117,000, lower consulting costs for new product development of $110,000, and lower other expenses of $20,000, which were partially offset by an increase in stock-based compensation expense of $19,000 and travel expense of $1,000.

Sales and marketing expense

We had sales and marketing expense of $2,952,000 for the nine months ended September 30, 2016, a decrease of $857,000, or 23%, compared to $3,809,000 in the same period in 2015. The change was primarily due to lower salary expense of $198,000, lower travel expense of $181,000, lower facility expense of $165,000, lower trade show expense of $97,000, lower other expenses of $37,000, and lower stock-based compensation expense of $32,000 as compared to the same period in 2015. We also had lower sales commissions of $147,000. However, during the nine months ended September 30, 2016, we reclassified $103,000 of previously recorded commission expense as a reduction to the commission accrual because such previously recorded amounts were advances against future commissions to be earned by a sales representative.

Table of Contents

General and administrative expense

We had general and administrative expense of $2,236,000 for the nine months ended September 30 2016, a decrease of $366,000, or 14%, compared to $2,602,000 in the same period in 2015. The change was primarily due to lower stock-based compensation expense of $313,000, lower taxes and associated expense of $164,000, lower patent and legal expenses of $80,000, lower expense for uncollectable accounts of $52,000, lower insurance premium fees of $29,000, lower salaries and fees for employees, directors, and consultants of $21,000, and lower travel expenses of $2,000, which decreases were partially offset by higher costs associated with professional fees of $183,000, higher merchant fees and other expenses of $87,000, and higher technical support of $25,000.

Other expense

We had other expense of $282,000 for the nine months ended September 30, 2016, an increase of $203,000, or 257%, compared to $79,000 in the same period in 2015. The change was primarily due to higher interest expense of $201,000 associated with the issuance of promissory notes to lenders and higher credit card fees associated with our corporate credit card of $2,000.

Net loss

For the foregoing reasons, we had a net loss of $2,334,000, or $0.46 per share, for the nine months ended September 30, 2016, a decrease of $1,959,000, or 46%, compared to a net loss of $4,293,000, or $0.87 per share, for the same period in 2015.

Liquidity and Capital Resources

We had cash of $517,000 at September 30, 2016 compared to $405,000 at December 31, 2015, and total current liabilities of $3,317,000 at September 30, 2016 compared to $4,108,000 at December 31, 2015. As of September 30, 2016 we had negative working capital of approximately $1,769,000.

In January 2016, we borrowed an aggregate of $1,500,000 from Mr. William H.C. Chang pursuant to two separate promissory notes and also issued two 2-year warrants to acquire an aggregate 228,572 shares of our common stock at an exercise price of $1.75 per share. On March 31, 2016, we borrowed $700,000 from an accredited investor pursuant to a promissory note and also issued a 2-year warrant to acquire an aggregate 79,459 shares of our common stock at $1.85 per share. On April 5, 2016, we borrowed $160,000 from the same accredited investor pursuant to a promissory note and also issued a 2-year warrant to acquire an aggregate of 18,162 shares of our common stock at $1.85 per share. On May 20, 2016, we borrowed $80,000 from the same accredited investor pursuant to a promissory note and also issued a 2-year warrant to acquire an aggregate of 9,081 shares of our common stock at $1.85 per share. In July 2016 we entered into some software and equipment financing arrangements. Please see “—Description of Indebtedness” for additional information regarding these loans.

We have incurred recurring losses since inception and expect to continue to incur losses as a result of costs and expenses related to our marketing and other promotional activities, research and continued development of our products and services. Our principal sources of cash have included the issuance of equity, including our February 2014 initial public offering of common stock, and to a lesser extent, recent private placement offerings of common stock, borrowings under loan agreements, the issuance of promissory notes, and revenue from leasing our product and selling our testing services. We expect that our operating expenses will continue to grow in order to grow our revenues and, as a result, we will need to generate significant additional net revenues to achieve profitability. For these reasons, our independent registered public accountants’ report for the year ended December 31, 2015 includes an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.” This doubt continues to exist.

Although we do not have any current capital commitments, we expect that we may increase our expenditures to continue our efforts to grow our business and commercialize our products and services. Accordingly, we currently expect to make additional expenditures in both sales and marketing, and invest in our corporate infrastructure. We also expect to invest in our research and development efforts. We do not have any definitive plans as to the exact amounts or particular uses at this time, and the exact amounts and timing of any expenditure may vary significantly from our current intentions. However, in order to execute on our business plan, and given our current available cash, we anticipate that we will need to raise additional capital. To improve operating cash flow, in 2015, we implemented measures to reduce expenses and renegotiated longer payment terms in our existing contracts. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on acceptable terms or whether or not we will generate sufficient revenues to become profitable and have positive operating cash flow. If we are unable to raise sufficient additional funds when necessary, we may need to curtail making additional expenditures and could be required to scale back our business plans, or make other changes until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

Table of Contents

Operating activities

We used $1,906,000 of net cash in operating activities for the nine months ended September 30, 2016. Non-cash adjustments to reconcile net loss to net cash used in operating activities plus changes in operating assets and liabilities provided $428,000 of cash in the nine months ended September 30, 2016. These non-cash adjustments primarily reflect depreciation of $336,000, stock-based compensation expense of $222,000, loss on disposal of assets for lease of $149,000, amortization of debt discount costs of $133,000, and allowance for doubtful accounts of $66,000. Cash used in operating activities was primarily from trade accounts payable of $558,000, deferred revenue of $285,000, and prepaid expenses and other current assets of $80,000, partially offset by net cash provided by trade accounts receivable of $315,000 and accrued expenses of $130,000.

For the same period in 2015, we used $2,491,000 of net cash in operating activities. Non-cash adjustments to reconcile net loss to net cash used in operating activities plus changes in operating assets and liabilities provided $1,802,000 of cash in the nine months ended September 30, 2015. These non-cash adjustments primarily reflect stock-based compensation expense of $549,000, depreciation of $211,000, allowance for doubtful accounts of $119,000, loss on disposal of assets for lease of $106,000, and amortization of deferred financing costs and debt discounts of $55,000. Cash used in operating activities was primarily from trade accounts receivable of $203,000, and accounts payable of $28,000, partially offset by net cash provided by deferred revenue of $716,000, accrued expenses of $237,000, and prepaid expenses and other current assets of $40,000.

Investing activities

We used $555,000 of net cash in investing activities for the nine months ended September 30, 2016, primarily from purchases of assets for lease of $415,000 and fixed asset purchases of $140,000. We generated $1,421,000 of net cash in investing activities for the same period in 2015, primarily from a change in restricted cash of $2,100,000, partially offset by purchases of assets for lease of $484,000 and fixed asset purchases of $195,000.

Financing activities

We generated $2,573,000 in net cash in financing activities during the nine months ended September 30, 2016 due to proceeds from loans payable of $2,590,000, partially offset by payments of loans payable of $17,000. We used $1,161,000 of net cash from financing activities during the same period in 2015, primarily from payments of loans of $2,000,000 and offering costs of $174,000, partially offset by $999,000 from the sale of shares of our common stock and $14,000 from exercise of stock options.

Description of Indebtedness

In January 2016, we borrowed an aggregate of $1,500,000 from William H.C. Chang, a significant stockholder, pursuant to two separate 2-year promissory notes. The notes bear simple interest ($1.0 million at a rate of 10% per annum, and $0.5 million at 5% per annum) and mature in two years, with all principal and accrued but unpaid interest payable at maturity. We may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and we agreed not to incur additional indebtedness in excess of $50,000 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, we issued the Chang Family Trust a two-year warrant to purchase an aggregate of 228,372 shares of our common stock at an exercise price of $1.75 per share. The warrants may not be exercised, however, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 19.99% of our common stock.

In March 2016, we borrowed an aggregate of $700,000 from an accredited investor, pursuant to a two-year promissory note. The note bears simple interest at a rate of 10% per annum and matures in two years, with all principal and accrued but unpaid interest payable at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, we issued a two-year warrant to purchase an aggregate of 79,459 shares of our common stock at an exercise price of $1.85 per share. The warrants may not be exercised, however, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 4.99% of our common stock

In April 2016, we borrowed an aggregate of $160,000 from an accredited investor, pursuant to a two-year promissory note. The note bears simple interest at a rate of 10% per annum and matures in two years, with all principal and accrued but unpaid interest payable at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, we issued a two-year warrant to purchase an aggregate of 18,162 shares of our common stock at an exercise price of $1.85 per share. The warrants may not be exercised, however, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 4.99% of our common stock.

In May 2016, we borrowed an aggregate of $80,000 from an accredited investor, pursuant to a two-year promissory note. The note bears simple interest at a rate of 10% per annum and matures in two years, with all principal and accrued but unpaid interest

Table of Contents

payable at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, we issued a two-year warrant to purchase an aggregate of 9,081 shares of our common stock at an exercise price of $1.85 per share. The warrants may not be exercised, however, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 4.99% of our common stock.

In addition to the above, we have also entered into other debt financing arrangements, including equipment and software financing arrangements. See Note 6 to our financial statements appearing elsewhere in this report for a description of our outstanding indebtedness.

Off-Balance Sheet Arrangements

As of each of September 30, 2016 and December 31, 2015, we had no off-balance sheet arrangements.

Commitments and Contingencies

As of each of September 30, 2016 and December 31, 2015, other than employment/consulting agreements with key executive officers and our facilities lease obligation, we had no material commitments other than the liabilities reflected in our financial statements.

JOBS Act

In April 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this extended transition period, and, as a result, we will not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

In evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our management, with the participation of our chief executive officer and our vice president, finance, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q. Based on that evaluation, our chief executive officer and our vice president, finance concluded that our disclosure controls and procedures were not effective, at the reasonable assurance level as of the end of the period covered by that report, to ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934 (1) is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (2) is accumulated and communicated to management, including our chief executive officer and our vice president, finance as appropriate to allow timely decisions regarding required disclosure, due to the existence of the material weaknesses in our internal control over financial reporting.

Table of Contents

Changes in Internal Control over Financial Reporting

In an effort to remediate the material weaknesses in our internal control over financial reporting, in early 2016 we began adopting and implementing policies and procedures with respect to the review, supervision, and monitoring of our accounting and reporting functions. We will continue assessing our procedures to improve our internal control over financial reporting. Other than these changes, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during our third fiscal quarter of 2016.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

Not applicable.

Item 1A. Risk Factors.

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Not applicable.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Not applicable.

Item 6. Exhibits.

Exh. No.		Exhibit Name
31.1		Rule 13a-14(a) Certification of Principal Executive Officer of Registrant
31.2		Rule 13a-14(a) Certification of Principal Financial Officer of Registrant
32		Section 1350 Certification

101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Extension Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

November 3, 2016	SEMLER SCIENTIFIC, INC.

	By:	/s/ Douglas Murphy-Chutorian, M.D.
		Douglas Murphy-Chutorian, M.D.
		Chief Executive Officer

	By:	/s/ Daniel Conger
		Daniel Conger
		Vice-President, Finance Principal Accounting Officer

EX-31.1 2 t1602555_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATIONS

I, Douglas Murphy-Chutorian, M.D., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Semler Scientific, Inc., a Delaware corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 3, 2016
	/s/ Douglas Murphy-Chutorian, M.D.
	Douglas Murphy-Chutorian, M.D
	Chief Executive Officer

EX-31.2 3 t1602555_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

I, Daniel Conger, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Semler Scientific, Inc., a Delaware corporation;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 3, 2016

	/s/ Daniel Conger
	Daniel Conger, Vice-President, Finance
	(Principal Accounting Officer)

EX-32 4 t1602555_ex32.htm EXHIBIT 32

Exhibit 32

SECTION 1350 CERTIFICATION

Each of the undersigned, Douglas Murphy-Chutorian, M.D., Chief Executive Officer of Semler Scientific, Inc., a Delaware corporation (the “Company”), and Daniel Conger, Vice-President, Finance of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge (1) the quarterly report on Form 10-Q of the Company for the period ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Douglas Murphy-Chutorian, M.D.
	Name: Douglas Murphy-Chutorian, M.D.
	Title: Chief Executive Officer
	Dated: November 3, 2016

	/s/ Daniel Conger
	Name: Daniel Conger
	Title: Vice-President, Finance Dated: November 3, 2016
	(Principal Accounting Officer)

This certification accompanies and is being “furnished” with this Report, shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 smlr-20160930.xml XBRL INSTANCE FILE 0001554859 smlr:LeaseAgreementMember 2014-09-01 2014-09-23 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember 2015-01-01 2015-01-31 0001554859 smlr:SubLeaseAgreementMember 2015-07-01 2015-07-15 0001554859 2015-07-01 2015-09-30 0001554859 us-gaap:WarrantMember 2015-07-01 2015-09-30 0001554859 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001554859 us-gaap:CostOfSalesMember 2015-07-01 2015-09-30 0001554859 smlr:EngineeringAndProductDevelopmentMember 2015-07-01 2015-09-30 0001554859 us-gaap:SellingAndMarketingExpenseMember 2015-07-01 2015-09-30 0001554859 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001554859 us-gaap:MinimumMember 2015-07-01 2015-09-30 0001554859 us-gaap:MaximumMember 2015-07-01 2015-09-30 0001554859 2015-01-01 2015-09-30 0001554859 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001554859 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001554859 us-gaap:CostOfSalesMember 2015-01-01 2015-09-30 0001554859 smlr:EngineeringAndProductDevelopmentMember 2015-01-01 2015-09-30 0001554859 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-09-30 0001554859 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001554859 us-gaap:MinimumMember 2015-01-01 2015-09-30 0001554859 us-gaap:MaximumMember 2015-01-01 2015-09-30 0001554859 2015-01-01 2015-12-31 0001554859 2015-12-31 0001554859 us-gaap:UnsecuredDebtMember smlr:FixedInterestRateOf10PercentMember 2016-01-15 0001554859 us-gaap:UnsecuredDebtMember smlr:FixedInterestRateOf10PercentMember 2016-01-02 2016-01-15 0001554859 us-gaap:UnsecuredDebtMember smlr:FixedInterestRateOfFivePercentMember 2016-01-21 0001554859 us-gaap:UnsecuredDebtMember smlr:FixedInterestRateOfFivePercentMember 2016-01-02 2016-01-21 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember 2016-01-01 2016-01-31 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember smlr:NonEmployeeDirectorMember 2016-02-18 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember smlr:NonEmployeeDirectorMember 2016-02-01 2016-02-18 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember us-gaap:BoardOfDirectorsChairmanMember 2016-02-01 2016-02-18 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember us-gaap:BoardOfDirectorsChairmanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-02-01 2016-02-18 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember us-gaap:BoardOfDirectorsChairmanMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2016-02-01 2016-02-18 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember us-gaap:BoardOfDirectorsChairmanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-02-01 2016-02-18 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-03-31 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-03-01 2016-03-31 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-04-05 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-04-01 2016-04-05 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-05-20 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-05-01 2016-05-20 0001554859 smlr:FixedInterestRateEightPointNinePercentMember smlr:AscentiumCapitalLlcMember smlr:SoftwareLicenseFinancingAgreementMember 2016-07-01 0001554859 smlr:FixedInterestRateEightPointNinePercentMember smlr:AscentiumCapitalLlcMember smlr:SoftwareLicenseFinancingAgreementMember 2016-06-30 2016-07-01 0001554859 smlr:FixedInterestRateEightPointNinePercentMember smlr:AscentiumCapitalLlcMember smlr:SoftwareLicenseFinancingAgreementMember 2016-07-08 0001554859 smlr:FixedInterestRateEightPointNinePercentMember smlr:AscentiumCapitalLlcMember smlr:SoftwareLicenseFinancingAgreementMember 2016-07-02 2016-07-08 0001554859 smlr:FixedInterestRateOfSevenPointThreePercentMember smlr:RoyalBankAmericaLeasingLpMember smlr:SecuredEquipmentFinancingAgreementMember 2016-07-11 0001554859 smlr:FixedInterestRateOfSevenPointThreePercentMember smlr:RoyalBankAmericaLeasingLpMember smlr:SecuredEquipmentFinancingAgreementMember 2016-07-02 2016-07-11 0001554859 smlr:FirstInstallmentMember smlr:FixedInterestRateOfSevenPointThreePercentMember smlr:RoyalBankAmericaLeasingLpMember smlr:SecuredEquipmentFinancingAgreementMember 2016-07-02 2016-07-11 0001554859 smlr:SecondInstallmentMember smlr:FixedInterestRateOfSevenPointThreePercentMember smlr:RoyalBankAmericaLeasingLpMember smlr:SecuredEquipmentFinancingAgreementMember 2016-07-02 2016-07-11 0001554859 smlr:ThirdInstallmentMember smlr:FixedInterestRateOfSevenPointThreePercentMember smlr:RoyalBankAmericaLeasingLpMember smlr:SecuredEquipmentFinancingAgreementMember 2016-07-02 2016-07-11 0001554859 smlr:TwelveMonthsMember smlr:FixedInterestRateOfSevenPointThreePercentMember smlr:RoyalBankAmericaLeasingLpMember smlr:SecuredEquipmentFinancingAgreementMember 2016-07-02 2016-07-11 0001554859 smlr:ThirteenToTwentyFourMonthsMember smlr:FixedInterestRateOfSevenPointThreePercentMember smlr:RoyalBankAmericaLeasingLpMember smlr:SecuredEquipmentFinancingAgreementMember 2016-07-02 2016-07-11 0001554859 smlr:TwentyFiveToThirtySixMonthsMember smlr:FixedInterestRateOfSevenPointThreePercentMember smlr:RoyalBankAmericaLeasingLpMember smlr:SecuredEquipmentFinancingAgreementMember 2016-07-02 2016-07-11 0001554859 2016-07-02 2016-09-30 0001554859 us-gaap:WarrantMember 2016-07-02 2016-09-30 0001554859 us-gaap:EmployeeStockOptionMember 2016-07-02 2016-09-30 0001554859 us-gaap:CostOfSalesMember 2016-07-02 2016-09-30 0001554859 smlr:EngineeringAndProductDevelopmentMember 2016-07-02 2016-09-30 0001554859 us-gaap:SellingAndMarketingExpenseMember 2016-07-02 2016-09-30 0001554859 us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-02 2016-09-30 0001554859 2016-01-01 2016-09-30 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001554859 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001554859 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001554859 us-gaap:CostOfSalesMember 2016-01-01 2016-09-30 0001554859 smlr:EngineeringAndProductDevelopmentMember 2016-01-01 2016-09-30 0001554859 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-09-30 0001554859 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0001554859 us-gaap:MinimumMember 2016-01-01 2016-09-30 0001554859 us-gaap:MaximumMember 2016-01-01 2016-09-30 0001554859 smlr:LeaseTermFromFebruary2015ToJanuary2016Member smlr:LeaseAgreementMember 2016-01-01 2016-09-30 0001554859 smlr:LeaseTermFromFebruary2016ToJanuary2017Member smlr:LeaseAgreementMember 2016-01-01 2016-09-30 0001554859 smlr:LeaseTermFromFebruary2017ToJanuary2018Member smlr:LeaseAgreementMember 2016-01-01 2016-09-30 0001554859 smlr:LeaseTermFromAugust2015ToJuly2016Member smlr:SubLeaseAgreementMember 2016-01-01 2016-09-30 0001554859 smlr:LeaseTermFromAugust2016ToJuly2017Member smlr:SubLeaseAgreementMember 2016-01-01 2016-09-30 0001554859 smlr:LeaseTermFromAugust2017ToJuly2018Member smlr:SubLeaseAgreementMember 2016-01-01 2016-09-30 0001554859 2016-09-30 0001554859 smlr:LeaseAgreementMember 2016-09-30 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember 2016-09-30 0001554859 smlr:SubLeaseAgreementMember 2016-09-30 0001554859 smlr:KeyPersonStockOptionPlan2007Member us-gaap:EmployeeStockOptionMember 2016-09-30 0001554859 2016-10-28 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember 2015-10-01 2015-10-31 0001554859 2014-12-31 0001554859 2015-09-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure Semler Scientific, Inc. 0001554859 smlr --12-31 Smaller Reporting Company 5123568 10-Q 2016-09-30 false 2016 Q3

1562000

4067000

1982000

5118000

385000

887000

398000

1348000

268000

983000

183000

634000

1314000

3809000

950000

2952000

1147000

2602000

706000

2236000

3114000

8281000

2237000

7170000

-1552000

-4214000

-255000

-2052000

-28000

-79000

-107000

-282000

-1580000

-4293000

-362000

-2334000

-0.32

-0.87

-0.07

-0.46

4983198

4909354

5123568

405000

517000

4156000

1925000

1278000

897000

69000

134000

1752000

1548000

830000

853000

497000

544000

15000

3079000

2960000

839000

281000

2317000

2297000

952000

667000

4108000

3317000

43000

55000

138000

920000

43000

2449000

5000

21291000

21891000

-22368000

-24702000

-1072000

-2806000

3079000

2960000

1336000

183000

76000

80000

0.001

50000000

5148568

5123568

25000

0 164000

55000

133000

211000

336000

-106000

-149000

119000

66000

549000

222000

203000

-315000

-40000

80000

-28000

-558000

237000

130000

716000

-285000

-2491000

-1906000

195000

140000

484000

415000

1421000

-555000

999000

14000

174000

2590000

-1161000

2573000

-2231000

112000

19000

3000

322000

<div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 27pt; text-align: left;">5.</td> <td style="text-align: justify;">Accrued Expenses</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accrued expenses consist of the following: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">September 30,  2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">December 31,  2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td> </td> <td style="text-align: right;" colspan="2" nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right;" colspan="2" nowrap="nowrap"> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 870px; text-align: left;">Offering Costs</td> <td style="width: 12px;"> </td> <td style="width: 12px; text-align: left;">$</td> <td style="width: 118px; text-align: right;">227</td> <td style="width: 12px; text-align: left;"> </td> <td style="width: 12px;"> </td> <td style="width: 11px; text-align: left;">$</td> <td style="width: 117px; text-align: right;">227</td> <td style="width: 11px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Compensation</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,443</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,093</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-bottom: 1pt;">Miscellaneous Accruals</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">627</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">997</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2.5pt;">Total Accrued Expenses</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,297</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,317</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accumulated offering costs that were accrued pertain to consulting fees associated with securing equity financing for the Company prior to the initial public offering. Prior to becoming Chief Executive Officer (“CEO”), the Company’s current CEO performed consulting services for the Company, which included managing finance, sales, marketing, operational and strategic planning for the Company, as well as assistance and strategic guidance in securing financing. The Company has agreed to a payment date of December 31, 2016 for these fees.</div> </div>

<table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 1641px; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 0px;"></td> <td style="text-align: left; width: 27pt;">6.</td> <td style="text-align: justify;">Commitments and Contingencies</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Facilities Leases <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Facilities lease expense recognized by the Company was $16 and $93 for the three months ended September 30, 2016 and 2015, respectively. Facilities lease expense recognized by the Company was $53 and $194 for the nine months ended September 30, 2016 and 2015, respectively. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On September 23, 2014, the Company entered into a 36-month lease agreement for office space for the sales and marketing team located in Menlo Park, CA. The lease term commenced February 1, 2015 and is effective through January 31, 2018. Payments required under the terms of the lease are $17.0 per month from February 2015 to January 2016, $17.5 per month from February 2016 to January 2017, and $18.0 per month from February 2017 to January 2018. The Company anticipates total future lease payments of $52.4 for the year ended December 31, 2016; $215.4 for the year ended December 31, 2017; and $18.0 for the year ended December 31, 2018. On July 15, 2015, the Company entered into a 30-month sublease agreement for the Menlo Park office space, which commenced August 1, 2015 and is effective through the term of the lease, January 31, 2018. Payments required to the Company under the terms of the sublease are $15.5 per month from August 2015 to July 2016, $16.0 per month from August 2016 to July 2017, and $16.5 per month from August 2017 to January 2018. The Company anticipates receipt of total future sublease payments of $48.0 for the year ended December 31, 2016; $194.4 for the year ended December 31, 2017; and $16.5 for the year ended December 31, 2018. The Company recorded an expense of $50, which represented the difference between estimated cash payments on the lease and cash receipts from the sublease. The Company recorded the resulting long-term liability as deferred rent on the Company’s balance sheet. The cease use date is July 31, 2015. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">   <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Loans Payable <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Loans from Related Parties <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On January 15, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $1,000 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $1,000 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On January 21, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $500 unsecured loan for a 24-month term at a fixed interest rate of 5% per annum. Under the loan agreement, the Company will pay $500 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Other Loans <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On March 31, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $700 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $700 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 79,459 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On April 5, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $160 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $160 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 18,162 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On May 20, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $80 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $80 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 9,081 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company uses the Black-Scholes pricing model to determine the relative fair market value of warrants. The relative fair market value of each warrant is estimated on the date of grant. There were no warrants issued during the three months ended September 30, 2016 or 2015. The relative fair value of the warrants granted is estimated on the date of grant using the Black-Scholes pricing model and the following assumptions for the periods presented: <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="widows: 2; text-transform: none; text-indent: 0px; width: 1231px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Nine months ended September 30,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; width: 912px;">Expected term (in years)</td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;"> </td> <td style="text-align: right; width: 123px;">2</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;"> </td> <td style="text-align: right; width: 123px;">-</td> <td style="text-align: left; width: 12px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Risk-free interest rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.73 – 0.89</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Expected volatility</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">97.7 – 99.0</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Expected dividend rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The assumptions are based on the following for each of the years presented: <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Valuation Method — The Company estimates the relative fair value of warrants using the Black-Scholes pricing model. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Expected Term — The Company uses the amount of time the warrants are exercisable per the contractual terms of the award. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Volatility — Because the Company has limited trading history by which to determine the volatility of its own common stock price, the expected volatility being used is derived from the historical stock volatilities of a representative industry peer group of comparable publicly listed companies over a period approximately equal to the expected term of the warrants. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the warrants. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Expected Dividend — The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On July 1, 2016, the Company entered into a software license financing agreement with Ascentium Capital, LLC. Pursuant to the agreement, the Company obtained a $39 loan for a 12-month term at a fixed interest rate of 8.9% per annum. to finance its upfront software licensing fee. The Company has no obligation to make any payments during the first three months, and agreed to pay $4.6 of principal and accrued interest for each of the last 9 months of the term. The loan may be prepaid at any time prior to maturity without penalty. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On July 8, 2016, the Company entered into an additional software license financing agreement with Ascentium Capital, LLC. Pursuant to the agreement, the Company obtained a $74 loan for a 36-month term at a fixed interest rate of 8.9% per annum. Under the loan agreement, the Company agreed to make monthly payments of $2.4 of principal and accrued interest. The loan may be prepaid at any time prior to maturity without penalty. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On July 11, 2016, the Company entered into a secured equipment financing agreement with Royal Bank America Leasing, L.P. Pursuant to the agreement, the Company obtained a $150 loan for a 36-month term at a fixed interest rate of 9.3% per annum, which is secured by related equipment. The loan is to be disbursed in three installments. The first installment was for $37. The second installment for $52 will be disbursed in July 2017, and the third installment for $61 will be disbursed in July 2018. Under the loan agreement, the Company will pay $3.5 of principal and accrued interest for each of the first 12 months, $4.4 of principal and accrued interest for each of months 13-24, and $5.3 of principal and accrued interest for each of months 25-36. The loan may be prepaid at any time only in accordance with the agreement. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">For the three months ended September 30, 2016 and 2015 interest expense was $105 and $25, respectively. Of this total interest expense, the portion related to amortization of debt discount was $50 and $18, respectively. For the nine months ended September 30, 2016 and 2015 interest expense was $275 and $74, respectively. Of this total interest expense, the portion related to amortization of debt discount was $133 and $55, respectively. <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Indemnification Obligations <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27.35pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27.35pt; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company enters into agreements with customers, partners, lenders, consultants, lessors, contractors, sales representatives and parties to certain transactions in the ordinary course of the Company’s business. These agreements may require the Company to indemnify the other party against third party claims alleging that its product infringes a patent or copyright. Certain of these agreements require the Company to indemnify the other party against losses arising from: a breach of representations or covenants, claims relating to property damage, personal injury or acts or omissions of the Company, its employees, agents or representatives. The Company has also agreed to indemnify the directors and certain of the officers and employees in accordance with the by-laws of the Company. These indemnification provisions will vary based upon the nature and terms of the agreements. In many cases, these indemnification provisions do not contain limits on the Company’s liability, and the occurrence of contingent events that will trigger payment under these indemnities is difficult to predict. As a result, the Company cannot estimate its potential liability under these indemnities. The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company had not made any significant payment under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. In certain cases, the Company has recourse against third parties with respect to the aforesaid indemnities, and the Company believes it maintains adequate levels of insurance coverage to protect the Company with respect to potential claims arising from such agreements.

<div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 27pt; text-align: left;">7.</td> <td style="text-align: justify;">Net Loss Per Common Share</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Because the Company was in a loss position for each of the periods presented, diluted net loss per share is the same as basic net loss per share for each period as the inclusion of all potential common shares outstanding would have been anti-dilutive. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been anti-dilutive: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.4in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Three months ended September 30,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Nine months ended September 30,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td>Weighted average shares outstanding:</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 639px; text-align: left;">Common stock warrants</td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 134px; text-align: right;">722,988</td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 13px;"> </td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 133px; text-align: right;">359,714</td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 13px;"> </td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 133px; text-align: right;">671,516</td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 13px;"> </td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 133px; text-align: right;">359,714</td> <td style="width: 13px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding-bottom: 1pt;">Options</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2,069,517</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">852,040</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2,041,515</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">768,236</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,792,505</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">1,211,754</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,713,031</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">1,127,950</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table> </div>

<div> <table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 27pt; text-align: left;">8.</td> <td style="text-align: justify;">Stock Option Plan</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company’s stock-based compensation program is designed to attract and retain employees while also aligning employees' interests with the interests of its stockholders. Stock options have been granted to employees under the stockholder-approved 2007 Key Person Stock Option Plan (“2007 Plan”) or the stockholder-approved 2014 Stock Incentive Plan (“2014 Plan”). Stockholder approval of the 2014 Plan became effective in September 2014. The 2014 Plan originally provided that the aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2014 Plan may not exceed 450,000 shares (the “Share Reserve”), however in October 2015, the stockholders approved a 1,500,000 increase to the Share Reserve. In addition, the Share Reserve automatically increases on January 1st of each year, for a period of not more than 10 years, beginning on January 1st of the year following the year in which the 2014 Plan became effective and ending on (and including) January 1, 2024, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Company’s Board of Directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise occur. On January 1, 2015, the Share Reserve increased by 188,640 shares due to the automatic 4% increase. On January 1, 2016, the Share Reserve increased by 204,943 shares due to the automatic 4% increase. The Share Reserve is currently 2,343,583 shares for the year ending December 31, 2016.</div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In light of stockholder approval of the 2014 Plan, the Company no longer grants equity awards under the 2007 Plan. As of September 30, 2016, 0 shares of an aggregate total of 407,500 shares were available for future stock-based compensation grants under the 2007 Plan and 666,121 shares of an aggregate total of 2,343,583 shares were available for future stock-based compensation grants under the 2014 Plan. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Aggregate intrinsic value represents the difference between the closing market value as of September 30, 2016 of the underlying common stock and the exercise price of outstanding, in-the-money options. A summary of the Company’s stock option activity and related information for the nine months ended September 30, 2016 is as follows: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="14" nowrap="nowrap">Options Outstanding</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Number of Stock Options Outstanding</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted Average Remaining Contractual Term (In Years)</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Aggregate Intrinsic Value  (in thousands)</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 707px; font-weight: bold;">Balance, January 1, 2016</td> <td style="width: 15px; font-weight: bold;"> </td> <td style="width: 15px; text-align: left; font-weight: bold;"> </td> <td style="width: 148px; text-align: right; font-weight: bold;">1,909,911</td> <td style="width: 15px; text-align: left; font-weight: bold;"> </td> <td style="width: 15px; font-weight: bold;"> </td> <td style="width: 15px; text-align: left; font-weight: bold;">$</td> <td style="width: 148px; text-align: right; font-weight: bold;">2.58</td> <td style="width: 15px; text-align: left; font-weight: bold;"> </td> <td style="width: 15px; font-weight: bold;"> </td> <td style="width: 14px; text-align: left; font-weight: bold;"> </td> <td style="width: 147px; text-align: right; font-weight: bold;">8.56</td> <td style="width: 14px; text-align: left; font-weight: bold;"> </td> <td style="width: 14px; font-weight: bold;"> </td> <td style="width: 14px; text-align: left; font-weight: bold;">$</td> <td style="width: 147px; text-align: right; font-weight: bold;">813</td> <td style="width: 14px; text-align: left; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Options granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">160,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.23</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Options exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Options forfeited/canceled</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">394</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3.44</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-weight: bold;">Balance, September 30, 2016</td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;"> </td> <td style="text-align: right; font-weight: bold;">2,069,517</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">2.58</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;"> </td> <td style="text-align: right; font-weight: bold;">7.93</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">389</td> <td style="text-align: left; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-weight: bold;">Exercisable as of September 30, 2016</td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;"> </td> <td style="text-align: right; font-weight: bold;">1,670,236</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">2.60</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;"> </td> <td style="text-align: right; font-weight: bold;">7.74</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">389</td> <td style="text-align: left; font-weight: bold;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The total compensation cost related to unvested stock option awards not yet recognized was $639 as of September 30, 2016. The weighted average period over which the total unrecognized compensation cost related to these unvested stock awards will be recognized is 2.27 years. The estimated fair value of option shares vested during the quarters ended September 30, 2016 and 2015 was $87 and $485, respectively. The estimated fair value of option shares vested during the nine months ended September 30, 2016 and 2015 was $222 and $549, respectively. The weighted average fair value of options granted during the quarter ended September 30, 2015 was $2.26 per share, or an aggregate grant date fair value of $1,965. There were no options granted during the quarter ended September 30, 2016. The weighted average fair value of options granted during the nine months ended September 30, 2016 and 2015 was $1.43 per share and $2.17 per share, respectively, or an aggregate grant date fair value of $229 and $2,161, respectively. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5.85pt; text-align: justify; color: #000000; text-transform: none; text-indent: 19.95pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">On February 18, 2016 the Compensation Committee of the Company’s Board of Directors granted, and the full Board ratified, an option to acquire an aggregate of 125,000 shares under the 2014 Plan to the Company’s CEO. This option vests 25% on the one-year anniversary of the grant date and monthly thereafter for 36 months, such that the option is vested in full on the four-year anniversary of the grant date. On February 18, 2016 the Company’s Compensation Committee granted, and the full Board ratified, options to each of the then-seated non-employee Directors to acquire 5,000 shares, for an aggregate of 35,000 shares, under the 2014 Plan. These options vest on the one-year anniversary of their grant date. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Determining the Fair Value of Stock Options <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company uses the Black-Scholes pricing model to determine the fair value of stock options. The fair value of each option grant is estimated on the date of the grant. The following assumptions for the periods presented were: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Three months ended September 30,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Nine months ended September 30,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 707px; text-align: left;">Expected term (in years)</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 148px; text-align: right;">-</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 148px; text-align: right;">5</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 147px; text-align: right;">5</td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 147px; text-align: right;">5</td> <td style="width: 14px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Risk-free interest rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.5 – 1.7</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.21</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.5 – 1.7</td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Expected volatility</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">83.0</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">80.4</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">82.9</td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Expected dividend rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> </tr> </table> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The assumptions are based on the following for each of the years presented: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Valuation Method — The Company estimates the fair value of its stock options using the Black-Scholes option pricing model. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Expected Term — The Company estimates the expected term consistent with the simplified method identified by the SEC. The Company elected to use the simplified method because of its limited history of stock option exercise activity and its stock options meet the criteria of the “plain-vanilla” options as defined by the SEC. The simplified method calculates the expected term as the average of the vesting and contractual terms of the award. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Volatility — Because the Company has limited trading history by which to determine the volatility of its own common stock price, the expected volatility being used is derived from the historical stock volatilities of a representative industry peer group of comparable publicly listed companies over a period approximately equal to the expected term of the options. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the options. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Expected Dividend — The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Forfeiture — The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and records stock-based compensation expense only for those awards that are expected to vest. All stock-based payment awards are amortized on a straight-line basis over the requisite service periods of the awards, which are generally the vesting periods. If the Company’s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company has recorded an expense of $87 and $485 as it relates to stock-based compensation for the three months ended September 30, 2016 and 2015, respectively. The Company has recorded an expense of $222 and $549 as it relates to stock-based compensation for the nine months ended September 30, 2016 and 2015, respectively, which was allocated as follows based on the role and responsibility of the recipient in the Company: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Three months ended September 30,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Nine months ended September 30</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 707px;">Cost of Revenue</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 148px; text-align: right;">1</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 148px; text-align: right;">1</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 147px; text-align: right;">1</td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 147px; text-align: right;">2</td> <td style="width: 14px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Engineering and Product Development</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">16</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">9</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">34</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">15</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Sales and Marketing</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">27</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">77</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">70</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">102</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1pt;">General and Administrative</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">43</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">398</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">117</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">430</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">87</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">485</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">222</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">549</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table> </div>

<table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 27pt; text-align: left;">9.</td> <td style="text-align: justify;">Subsequent Events</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 22.5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">None.

<table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Three months ended September 30,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Nine months ended September 30,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td>Weighted average shares outstanding:</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 639px; text-align: left;">Common stock warrants</td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 134px; text-align: right;">722,988</td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 13px;"> </td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 133px; text-align: right;">359,714</td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 13px;"> </td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 133px; text-align: right;">671,516</td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 13px;"> </td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 133px; text-align: right;">359,714</td> <td style="width: 13px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding-bottom: 1pt;">Options</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2,069,517</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">852,040</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2,041,515</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">768,236</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,792,505</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">1,211,754</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,713,031</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">1,127,950</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

<div> <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="14" nowrap="nowrap">Options Outstanding</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Number of Stock Options Outstanding</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted Average Remaining Contractual Term (In Years)</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Aggregate Intrinsic Value  (in thousands)</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 707px; font-weight: bold;">Balance, January 1, 2016</td> <td style="width: 15px; font-weight: bold;"> </td> <td style="width: 15px; text-align: left; font-weight: bold;"> </td> <td style="width: 148px; text-align: right; font-weight: bold;">1,909,911</td> <td style="width: 15px; text-align: left; font-weight: bold;"> </td> <td style="width: 15px; font-weight: bold;"> </td> <td style="width: 15px; text-align: left; font-weight: bold;">$</td> <td style="width: 148px; text-align: right; font-weight: bold;">2.58</td> <td style="width: 15px; text-align: left; font-weight: bold;"> </td> <td style="width: 15px; font-weight: bold;"> </td> <td style="width: 14px; text-align: left; font-weight: bold;"> </td> <td style="width: 147px; text-align: right; font-weight: bold;">8.56</td> <td style="width: 14px; text-align: left; font-weight: bold;"> </td> <td style="width: 14px; font-weight: bold;"> </td> <td style="width: 14px; text-align: left; font-weight: bold;">$</td> <td style="width: 147px; text-align: right; font-weight: bold;">813</td> <td style="width: 14px; text-align: left; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Options granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">160,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.23</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Options exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Options forfeited/canceled</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">394</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3.44</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-weight: bold;">Balance, September 30, 2016</td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;"> </td> <td style="text-align: right; font-weight: bold;">2,069,517</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">2.58</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;"> </td> <td style="text-align: right; font-weight: bold;">7.93</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">389</td> <td style="text-align: left; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-weight: bold;">Exercisable as of September 30, 2016</td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;"> </td> <td style="text-align: right; font-weight: bold;">1,670,236</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">2.60</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;"> </td> <td style="text-align: right; font-weight: bold;">7.74</td> <td style="text-align: left; font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">389</td> <td style="text-align: left; font-weight: bold;"> </td> </tr> </table> </div>

<table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Three months ended September 30,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Nine months ended September 30,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 707px; text-align: left;">Expected term (in years)</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 148px; text-align: right;">-</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 148px; text-align: right;">5</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 147px; text-align: right;">5</td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 147px; text-align: right;">5</td> <td style="width: 14px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Risk-free interest rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.5 – 1.7</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.21</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.5 – 1.7</td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Expected volatility</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">83.0</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">80.4</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">82.9</td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Expected dividend rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> </tr> </table>

<table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Three months ended September 30,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Nine months ended September 30</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 707px;">Cost of Revenue</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 148px; text-align: right;">1</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 148px; text-align: right;">1</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 147px; text-align: right;">1</td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 147px; text-align: right;">2</td> <td style="width: 14px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Engineering and Product Development</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">16</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">9</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">34</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">15</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Sales and Marketing</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">27</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">77</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">70</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">102</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1pt;">General and Administrative</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">43</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">398</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">117</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">430</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">87</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">485</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">222</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">549</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

1769000

1280000

1338000

450000

485000

72000

195000

81000

243000

34000 75000 91000 208000

542000

681000

45000

137000

10000

16000

33000

92000

227000 227000

1093000

1443000

997000

627000

P2Y

0.0073

0.0089

0.977

0.990

0.00

P36M

P30M

17000 17500 18000 15500 16000 16500

52400

48000

215400

194400

18000

16500

93000

194000

16000

53000

1000000

500000

700000

160000

80000

39000

74000

150000

P24M

P12M

P36M

0.10

0.05

0.1000

0.10

0.089

0.093

1000000

500000

700000

160000

80000

4600

2400

37000

52000

61000

3500

4400

5300

50000

114286

79459

18162

9081

1.75

1.85

P2Y P2Y P2Y P2Y P2Y more than 19.99% more than 19.99% more than 4.99% more than 4.99% more than 4.99%

25000

74000

105000

275000

18000

55000

50000

133000

1211754

359714

852040

1127950

359714

768236

2792505

722988

2069517

2713031

671516

2041515

1909911

2069517

5000

125000

160000

394

1670236

2.58

2.23

3.44

2.60

P8Y6M22D

P7Y11M5D

P7Y8M27D

813000

389000

P5Y

0.015

0.017

0.015

0.017

0.0121

0.830

0.829

0.804

0.00

485000

1000

9000

77000

398000

549000

2000

15000

102000

430000

87000

1000

16000

27000

43000

222000

1000

34000

70000

117000

0.0400 0.0400 0.0400

666121

35000

450000

407500

188640

204943

2343583

1500000

P10Y

639000

P2Y3M7D

485000

549000

87000

222000

2.26

2.17

1.43

1965000 2161000 229000

0.250

P36M

P4Y

P1Y

72000

-2100000

2000000

17000

50000

EX-101.SCH 6 smlr-20160930.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Assets for Lease, net link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Property and Equipment, net link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Net Loss Per Common Share link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Stock Option Plan link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Summary of Significant Accounting Policies and Estimates (Policies) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Assets for lease, net (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Stock Option Plan (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Going Concern (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Assets for Lease, net - Summary of assets for lease (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Assets for Lease, net (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Property and Equipment, net (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Accrued Expenses - Summary of accrued expenses (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Commitments and Contingencies (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Commitments and Contingencies (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Net Loss Per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Stock Option Plan - Summary of stock-based compensation activity (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Stock Option Plan - Weighted-average Black-Scholes fair value assumptions (Details 1) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Stock Option Plan - Stock-based compensation (Details 2) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Stock Option Plan (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Stock Option Plan (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 smlr-20160930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 smlr-20160930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 smlr-20160930_lab.xml XBRL LABEL FILE Document And Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Trading Symbol Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document Type Document Period End Date Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Income Statement [Abstract] Revenues Revenue Operating Expenses [Abstract] Operating expenses: Cost of Revenue Cost of revenue Technology Services Costs Engineering and product development Selling and Marketing Expense Sales and marketing General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Other Nonoperating Income (Expense) Other expense Other expense: Net Income (Loss) Attributable to Parent Net loss Net loss Net loss Net loss Earnings Per Share, Basic and Diluted Basic and diluted loss per share attributable to common stockholders (in dollars per share) Net loss per share, basic and diluted (in dollars per share) Basic and diluted loss per share attributable to common stockholders (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average shares outstanding (in shares) Weighted average number of shares used in computing basic and diluted loss per share (in shares) Statement of Financial Position [Abstract] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash CASH, BEGINNING OF PERIOD CASH, END OF PERIOD Accounts Receivable, Net, Current Trade accounts receivable, net of allowance for doubtful accounts of $76 and $183, respectively Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Capital Leases, Balance Sheet, Assets by Major Class, Net Assets for lease, net Assets for lease, net Property, Plant and Equipment, Net Capital assets, net Property and equipment, net Property and equipment, net Deposits Assets, Noncurrent Long-term deposits Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Deficit Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Accrued Expenses Total Accrued Expenses Loans Payable, Current Loans payable Deferred Revenue, Current Deferred revenue Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Long-term liabilities: Deferred rent Interest Payable, Noncurrent Accrued interest expense Represents the amount related to accrued interest expense. Due to Related Parties, Noncurrent Related party loan payable net of debt discount of $164 and $0, respectively Loans Payable, Noncurrent Loan payable net of debt discount of $80 and $0, respectively Liabilities, Noncurrent Total long-term liabilities Total long-term liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' deficit: Common Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized; 5,148,568 and 5,148,568 shares issued, and 5,123,568 and 5,123,568 outstanding (net of treasury shares of 25,000 and 25,000), respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Stockholders' deficit Total stockholders' deficit Balance Balance Liabilities and Equity Total liabilities and stockholders' deficit Allowance for Doubtful Accounts Receivable, Current Allowance for doubtful accounts on trade accounts receivable (in dollars) Debt Discount On Related Party Loan Debt discount on related party loan payable Represent amount of debt discount on Related party loan. Debt Instrument, Unamortized Discount Loan net of debt discount (in dollars) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Treasury Stock, Shares Treasury stock, shares Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Reconciliation of Net Loss to Net Cash Used in Operating Activities: Amortization of Financing Costs Amortized interest expense Amortization of debt discount Depreciation, Depletion and Amortization, Nonproduction Depreciation Gain (Loss) on Sale of Leased Assets, Net, Operating Leases Loss on disposal of assets for lease Loss on disposal of assets for lease Provision for Doubtful Accounts Reserve against its accounts receivable Allowance for doubtful accounts Share-based Compensation Stock-based compensation expense Stock-based compensation expense Increase (Decrease) in Operating Capital [Abstract] Changes in Operating Assets and Liabilities: Increase (Decrease) in Accounts Receivable Trade accounts receivable Trade accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Used in Operating Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments to Acquire Property, Plant, and Equipment Additions to property and equipment Additions to property and equipment Increase (Decrease) in Restricted Cash Change in restricted cash Change in restricted cash Payments to Acquire Equipment on Lease Purchase of assets for lease Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net Cash (Used in) Provided by Investing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from Issuance of Common Stock Issuance of common stock Proceeds from Stock Options Exercised Stock options exercised Payments of Stock Issuance Costs Offering costs Offering costs Proceeds from Long-term Lines of Credit Proceeds from loans payable Repayments of Long-term Debt Payments of loans payable Payments of loans payable Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) INCREASE (DECREASE) IN CASH Interest Paid Cash paid for interest Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of noncash financing activity: Fair Value Adjustment of Warrants Fair value of warrants issued to lenders Accounting Policies [Abstract] Basis of Accounting [Text Block] Basis of Presentation Basis of Accounting [Text Block] Going Concern [Abstract] Substantial Doubt about Going Concern [Text Block] Going Concern Leases, Capital [Abstract] Capital Leases in Financial Statements of Lessee Disclosure [Text Block] Assets for Lease, net Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property and Equipment, net Accrued Liabilities, Current [Abstract] Accrued Liabilities Disclosure [Text Block] Accrued Expenses The entire disclosure for accrued liabilities at the end of the reporting period. Commitments and Contingencies Disclosure [Abstract] Revolving line of credit, maximum limit Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Earnings Per Share [Abstract] Earnings Per Share [Text Block] Net Loss Per Common Share Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock Option Plan Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Option Plan Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Schedule of Capital Leased Assets [Table Text Block] Schedule of assets for lease Property, Plant and Equipment [Table Text Block] Schedule of property and equipment Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] Schedule of relative fair value of the warrants granted using the Black-Scholes pricing model Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of common stock equivalents excluded from the computation of diluted net loss per share Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of summary of stock-based compensation activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted-average Black-Scholes fair value assumptions Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of stock-based compensation based on the role and responsibility of the recipient in the Company Working Capital Surplus Deficit Working capital Working capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities. Working capital Capital Leased Assets, Gross Assets for lease Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation Less: Accumulated Depreciation Less: Accumulated depreciation Depreciation, Nonproduction Depreciation expense Depreciation Reduction In Accumulated Depreciation For Returned Items Reduction to accumulated depreciation for returned items This element represents reduction in accumulated depreciation for returned items. Property, Plant and Equipment, Gross Property and equipment Capital assets Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation Less: accumulated depreciation Depreciation Depreciation expense Depreciation Accrued Offering Costs Current Offering Costs This element represents carrying value of accrued offering cost as of balance sheet date. Employee-related Liabilities, Current Compensation Other Accrued Liabilities, Current Miscellaneous Accruals Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Range [Axis] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair Value Assumptions, Expected Term Expected term (in years) Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Fair Value Assumptions, Expected Volatility Rate Expected volatility Fair Value Assumptions, Expected Dividend Rate Expected dividend rate Property Subject to or Available for Operating Lease, by Major Property Class [Table] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Agreement [Member] Lease Agreement Represents information of operating lease. Sub Lease Agreement [Member] Sub Lease Agreement Represents information of sub lease agreement. Lease Agreement Period [Axis] Represents information of lease agreement. Lease Agreement Period [Domain] Represents information of lease agreement. Lease Term From February 2015 To January 2016 [Member] Lease term from February 2015 to January 2016 Represents information of term specified for lease agreement. Lease Term From February 2016 To January 2017 [Member] Lease term from February 2016 to January 2017 Represents information of term specified for lease agreement. Lease Term From February 2017 To January 2018 [Member] Lease term from February 2017 to January 2018 Represents information of term specified for lease agreement. Lease Term From August 2015 To July 2016 [Member] Lease term from August 2015 to July 2016 Represents information of term specified for lease agreement. Lease Term From August 2016 To July 2017 [Member] Lease term from August 2016 to July 2017 Represents information of term specified for lease agreement. Lease Term From August 2017 To July 2018 [Member] August 2017 to January 2018 Represents information of term specified for lease agreement. Property Subject to or Available for Operating Lease [Line Items] Lessee Leasing Arrangements, Operating Leases, Term of Contract Term specified for lease agreement Operating Leases Payments Required Per Month Payments required per month under terms of lease agreement Represents payments required per month under the terms of the lease agreement. Operating Leases, Future Minimum Payments Due, Next Twelve Months Future lease payments for December 31, 2016 Operating Leases, Future Minimum Payments, Due in Two Years Future lease payments for December 31, 2017 Operating Leases, Future Minimum Payments, Due in Three Years Future lease payments for December 31, 2018 Operating Leases, Rent Expense, Net Facilities lease expense Lease Expense Lease expense Represented the difference between estimated cash payments on the lease and cash receipts from the sublease. Commitments And Contingencies [Table] Represents information regarding commitments and contingencies of the entity. Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Unsecured Debt [Member] Unsecured Debt Fixed Rate [Axis] Represents information by fixed rate of interest rate. Fixed Rate [Domain] Represents information by fixed rate of interest. Fixed Interest Rate Of 10 Percent [Member] Fixed rate of interest 10% Represents fixed rate of interest. Fixed Interest Rate Of Five Percent Member Fixed rate of interest 5% Represents fixed rate of interest. Fixed Interest Rate Eight Point Nine Percent [Member] Fixed interest rate 8.9% Represents fixed interest rate of 8.9%. Fixed Interest Rate Of Seven Point Three Percent [Member] Fixed interest rate 7.3% Fixed Interest Rate Of Seven Point Three Percent. Title of Individual [Axis] Fixed rate of interest 10% Relationship to Entity [Domain] Investor [Member] Accredited investor Ascentium Capital Llc [Member] Ascentium Capital, LLC Ascentium Capital, LLC. Royal Bank America Leasing Lp [Member] Royal Bank America Leasing, L.P. Royal Bank America Leasing, L.P. Software License Financing Agreement [Member] Software license financing agreement Software license financing agreement. Secured Equipment Financing Agreement [Member] Secured equipment financing agreement Secured equipment financing agreement. Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] First Installment [Member] First installment First Installment. Second Installment [Member] Second installment Second Installment. Third Installment [Member] Third installment Third Installment. Twelve Months [Member] First 12 months Twelve Months. Thirteen To Twenty Four Months [Member] Each of months 13-24 Thirteen To Twenty Four Months. Twenty Five To Thirty Six Months [Member] Each of months 25-36 Twenty Five To Thirty Six Months. Commitments And Contingencies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Unsecured Debt Unsecured loan Debt Instrument, Term Term of secured loan EX-101.PRE 10 smlr-20160930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Oct. 28, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Semler Scientific, Inc.
Entity Central Index Key	0001554859
Trading Symbol	smlr
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		5,123,568
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenue	$ 1,982	$ 1,562	$ 5,118	$ 4,067
Operating expenses:
Cost of revenue	398	385	1,348	887
Engineering and product development	183	268	634	983
Sales and marketing	950	1,314	2,952	3,809
General and administrative	706	1,147	2,236	2,602
Total operating expenses	2,237	3,114	7,170	8,281
Loss from operations	(255)	(1,552)	(2,052)	(4,214)
Other expense	(107)	(28)	(282)	(79)
Net loss	$ (362)	$ (1,580)	$ (2,334)	$ (4,293)
Net loss per share, basic and diluted (in dollars per share)	$ (0.07)	$ (0.32)	$ (0.46)	$ (0.87)
Weighted average number of shares used in computing basic and diluted loss per share (in shares)	5,123,568	4,983,198	5,123,568	4,909,354

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash	$ 517	$ 405
Trade accounts receivable, net of allowance for doubtful accounts of $76 and $183, respectively	897	1,278
Prepaid expenses and other current assets	134	69
Total current assets	1,548	1,752
Assets for lease, net	853	830
Property and equipment, net	544	497
Long-term deposits	15
Total assets	2,960	3,079
Current liabilities:
Accounts payable	281	839
Accrued expenses	2,297	2,317
Loans payable	72
Deferred revenue	667	952
Total current liabilities	3,317	4,108
Long-term liabilities:
Deferred rent	55	43
Accrued interest expense	138
Related party loan payable net of debt discount of $164 and $0, respectively	1,336
Loan payable net of debt discount of $80 and $0, respectively	920
Total long-term liabilities	2,449	43
Stockholders' deficit:
Common stock, $0.001 par value; 50,000,000 shares authorized; 5,148,568 and 5,148,568 shares issued, and 5,123,568 and 5,123,568 outstanding (net of treasury shares of 25,000 and 25,000), respectively	5	5
Additional paid-in capital	21,891	21,291
Accumulated deficit	(24,702)	(22,368)
Total stockholders' deficit	(2,806)	(1,072)
Total liabilities and stockholders' deficit	$ 2,960	$ 3,079

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable (in dollars)	$ 76	$ 183
Debt discount on related party loan payable	164	0
Loan net of debt discount (in dollars)	$ 80	$ 0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	5,148,568	5,148,568
Common stock, shares outstanding	5,123,568	5,123,568
Treasury stock, shares	25,000	25,000

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,334)	$ (4,293)
Reconciliation of Net Loss to Net Cash Used in Operating Activities:
Amortization of debt discount	133	55
Depreciation	336	211
Loss on disposal of assets for lease	149	106
Allowance for doubtful accounts	66	119
Stock-based compensation expense	222	549
Changes in Operating Assets and Liabilities:
Trade accounts receivable	315	(203)
Prepaid expenses and other current assets	(80)	40
Accounts payable	(558)	(28)
Accrued expenses	130	237
Deferred revenue	(285)	716
Net Cash Used in Operating Activities	(1,906)	(2,491)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(140)	(195)
Change in restricted cash		2,100
Purchase of assets for lease	(415)	(484)
Net Cash (Used in) Provided by Investing Activities	(555)	1,421
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock		999
Stock options exercised		14
Offering costs		(174)
Proceeds from loans payable	2,590
Payments of loans payable	(17)	(2,000)
Net Cash Provided by (Used in) Financing Activities	2,573	(1,161)
INCREASE (DECREASE) IN CASH	112	(2,231)
CASH, BEGINNING OF PERIOD	405	4,156
CASH, END OF PERIOD	517	1,925
Cash paid for interest	3	$ 19
Supplemental disclosure of noncash financing activity:
Fair value of warrants issued to lenders	$ 322

XML 16 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

XML 17 R7.htm IDEA: XBRL DOCUMENT

Going Concern

9 Months Ended

Sep. 30, 2016

Going Concern [Abstract]

Going Concern

Going Concern

XML 18 R8.htm IDEA: XBRL DOCUMENT

Assets for Lease, net

9 Months Ended

Sep. 30, 2016

Leases, Capital [Abstract]

Assets for Lease, net

3.	Assets for Lease, net

Assets for lease consist of the following:

	September 30, 2016			December 31, 2015

Assets for lease	$	1,338		$	1,280
Less: Accumulated depreciation		(485	)		(450	)
Assets for lease, net	$	853		$	830

XML 19 R9.htm IDEA: XBRL DOCUMENT

Property and Equipment, net

9 Months Ended

Sep. 30, 2016

Property, Plant and Equipment [Abstract]

Property and Equipment, net

Property and Equipment, net

Property and equipment, net consists of the following:

	September 30, 2016			December 31, 2015

Property and equipment	$	681		$	542
Less: accumulated depreciation		(137	)		(45	)
Property and equipment, net	$	544		$	497

XML 20 R10.htm IDEA: XBRL DOCUMENT

Accrued Expenses

9 Months Ended

Sep. 30, 2016

Accrued Liabilities, Current [Abstract]

Accrued Expenses

Accrued Expenses

Accrued expenses consist of the following:

	September 30, 2016		December 31, 2015

Offering Costs	$	227	$	227
Compensation		1,443		1,093
Miscellaneous Accruals		627		997
Total Accrued Expenses	$	2,297	$	2,317

XML 21 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Facilities Leases

Loans Payable

Loans from Related Parties

Other Loans

On May 20, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $80 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $80 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 9,081 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

	Nine months ended September 30,
	2016			2015
Expected term (in years)		2			-
Risk-free interest rate		0.73 – 0.89	%		-
Expected volatility		97.7 – 99.0	%		-
Expected dividend rate		0	%		-

The assumptions are based on the following for each of the years presented:

Valuation Method — The Company estimates the relative fair value of warrants using the Black-Scholes pricing model.

Expected Term — The Company uses the amount of time the warrants are exercisable per the contractual terms of the award.

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the warrants.

Indemnification Obligations

XML 22 R12.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Net Loss Per Common Share

Net Loss Per Common Share

	Three months ended September 30,				Nine months ended September 30,
	2016		2015		2016		2015
Weighted average shares outstanding:
Common stock warrants		722,988		359,714		671,516		359,714
Options		2,069,517		852,040		2,041,515		768,236
Total		2,792,505		1,211,754		2,713,031		1,127,950

XML 23 R13.htm IDEA: XBRL DOCUMENT

Stock Option Plan

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option Plan

Stock Option Plan

	Options Outstanding
	Number of Stock Options Outstanding		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)		Aggregate Intrinsic Value (in thousands)
Balance, January 1, 2016		1,909,911	$	2.58		8.56	$	813
Options granted		160,000		2.23
Options exercised		-		-
Options forfeited/canceled		394		3.44
Balance, September 30, 2016		2,069,517	$	2.58		7.93	$	389
Exercisable as of September 30, 2016		1,670,236	$	2.60		7.74	$	389

Determining the Fair Value of Stock Options

	Three months ended September 30,					Nine months ended September 30,
	2016		2015			2016			2015
Expected term (in years)		-		5			5			5
Risk-free interest rate		-		1.5 – 1.7	%		1.21	%		1.5 – 1.7	%
Expected volatility		-		83.0	%		80.4	%		82.9	%
Expected dividend rate		-		0	%		0	%		0	%

The assumptions are based on the following for each of the years presented:

Valuation Method — The Company estimates the fair value of its stock options using the Black-Scholes option pricing model.

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the options.

	Three months ended September 30,				Nine months ended September 30
	2016		2015		2016		2015
Cost of Revenue	$	1	$	1	$	1	$	2
Engineering and Product Development		16		9		34		15
Sales and Marketing		27		77		70		102
General and Administrative		43		398		117		430
Total	$	87	$	485	$	222	$	549

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2016

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

None.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Estimates (Policies)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

XML 26 R16.htm IDEA: XBRL DOCUMENT

Assets for lease, net (Tables)

9 Months Ended

Sep. 30, 2016

Leases, Capital [Abstract]

Schedule of assets for lease

	September 30, 2016			December 31, 2015

Assets for lease	$	1,338		$	1,280
Less: Accumulated depreciation		(485	)		(450	)
Assets for lease, net	$	853		$	830

XML 27 R17.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Tables)

9 Months Ended

Sep. 30, 2016

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	September 30, 2016			December 31, 2015

Property and equipment	$	681		$	542
Less: accumulated depreciation		(137	)		(45	)
Property and equipment, net	$	544		$	497

XML 28 R18.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2016

Accrued Liabilities, Current [Abstract]

Schedule of accrued expenses

	September 30, 2016		December 31, 2015

Offering Costs	$	227	$	227
Compensation		1,443		1,093
Miscellaneous Accruals		627		997
Total Accrued Expenses	$	2,297	$	2,317

XML 29 R19.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of relative fair value of the warrants granted using the Black-Scholes pricing model

	Nine months ended September 30,
	2016			2015
Expected term (in years)		2			-
Risk-free interest rate		0.73 – 0.89	%		-
Expected volatility		97.7 – 99.0	%		-
Expected dividend rate		0	%		-

XML 30 R20.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Schedule of common stock equivalents excluded from the computation of diluted net loss per share

	Three months ended September 30,				Nine months ended September 30,
	2016		2015		2016		2015
Weighted average shares outstanding:
Common stock warrants		722,988		359,714		671,516		359,714
Options		2,069,517		852,040		2,041,515		768,236
Total		2,792,505		1,211,754		2,713,031		1,127,950

XML 31 R21.htm IDEA: XBRL DOCUMENT

Stock Option Plan (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of summary of stock-based compensation activity

	Options Outstanding
	Number of Stock Options Outstanding		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)		Aggregate Intrinsic Value (in thousands)
Balance, January 1, 2016		1,909,911	$	2.58		8.56	$	813
Options granted		160,000		2.23
Options exercised		-		-
Options forfeited/canceled		394		3.44
Balance, September 30, 2016		2,069,517	$	2.58		7.93	$	389
Exercisable as of September 30, 2016		1,670,236	$	2.60		7.74	$	389

Schedule of weighted-average Black-Scholes fair value assumptions

	Three months ended September 30,					Nine months ended September 30,
	2016		2015			2016			2015
Expected term (in years)		-		5			5			5
Risk-free interest rate		-		1.5 – 1.7	%		1.21	%		1.5 – 1.7	%
Expected volatility		-		83.0	%		80.4	%		82.9	%
Expected dividend rate		-		0	%		0	%		0	%

Schedule of stock-based compensation based on the role and responsibility of the recipient in the Company

	Three months ended September 30,				Nine months ended September 30
	2016		2015		2016		2015
Cost of Revenue	$	1	$	1	$	1	$	2
Engineering and Product Development		16		9		34		15
Sales and Marketing		27		77		70		102
General and Administrative		43		398		117		430
Total	$	87	$	485	$	222	$	549

XML 32 R22.htm IDEA: XBRL DOCUMENT

Going Concern (Detail Textuals) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Going Concern [Abstract]
Working capital	$ (1,769)
Cash	517	$ 405	$ 1,925	$ 4,156
Stockholders' deficit	$ (2,806)	$ (1,072)

XML 33 R23.htm IDEA: XBRL DOCUMENT

Assets for Lease, net - Summary of assets for lease (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Leases, Capital [Abstract]
Assets for lease	$ 1,338	$ 1,280
Less: Accumulated depreciation	(485)	(450)
Assets for lease, net	$ 853	$ 830

XML 34 R24.htm IDEA: XBRL DOCUMENT

Assets for Lease, net (Detail Textuals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Leases, Capital [Abstract]
Depreciation expense	$ 81	$ 72	$ 243	$ 195
Reduction to accumulated depreciation for returned items	$ 91	$ 34	$ 208	$ 75

XML 35 R25.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and equipment	$ 681	$ 542
Less: accumulated depreciation	(137)	(45)
Property and equipment, net	$ 544	$ 497

XML 36 R26.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Detail Textuals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 33	$ 10	$ 92	$ 16

XML 37 R27.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Summary of accrued expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Offering Costs	$ 227	$ 227
Compensation	1,443	1,093
Miscellaneous Accruals	627	997
Total Accrued Expenses	$ 2,297	$ 2,317

XML 38 R28.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)	9 Months Ended
Commitments and Contingencies (Details)	Sep. 30, 2016	Sep. 30, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected term (in years)	2 years
Risk-free interest rate
Expected volatility
Expected dividend rate	0.00%
Minimum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	0.73%
Expected volatility	97.70%
Maximum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	0.89%
Expected volatility	99.00%

XML 39 R29.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Detail Textuals) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 15, 2015	Sep. 23, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property Subject to or Available for Operating Lease [Line Items]
Facilities lease expense			$ 16,000	$ 93,000	$ 53,000	$ 194,000
Lease expense			50,000
Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Term specified for lease agreement		36 months
Future lease payments for December 31, 2016			52,400		52,400
Future lease payments for December 31, 2017			215,400		215,400
Future lease payments for December 31, 2018			18,000		18,000
Lease Agreement \| Lease term from February 2015 to January 2016
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement					17,000
Lease Agreement \| Lease term from February 2016 to January 2017
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement					17,500
Lease Agreement \| Lease term from February 2017 to January 2018
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement					18,000
Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Term specified for lease agreement	30 months
Future lease payments for December 31, 2016			48,000		48,000
Future lease payments for December 31, 2017			194,400		194,400
Future lease payments for December 31, 2018			$ 16,500		16,500
Sub Lease Agreement \| Lease term from August 2015 to July 2016
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement					15,500
Sub Lease Agreement \| Lease term from August 2016 to July 2017
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement					16,000
Sub Lease Agreement \| August 2017 to January 2018
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement					$ 16,500

XML 40 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Detail Textuals 1) - USD ($)						1 Months Ended			3 Months Ended		9 Months Ended
	Jul. 11, 2016	Jul. 08, 2016	Jul. 01, 2016	Apr. 05, 2016	Jan. 15, 2016	May 20, 2016	Mar. 31, 2016	Jan. 21, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Commitments And Contingencies [Line Items]
Interest expense									$ 105,000	$ 25,000	$ 275,000	$ 74,000
Amortization of debt discount									$ 50,000	$ 18,000	$ 133,000	$ 55,000
Fixed interest rate 8.9% \| Ascentium Capital, LLC \| Software license financing agreement
Commitments And Contingencies [Line Items]
Unsecured loan		$ 74,000	$ 39,000
Term of secured loan		36 months	12 months
Unsecured loan rate of interest		8.90%	8.90%
Unsecured loan principal and interest payment		$ 2,400	$ 4,600
Fixed interest rate 7.3% \| Royal Bank America Leasing, L.P. \| Secured equipment financing agreement
Commitments And Contingencies [Line Items]
Unsecured loan	$ 150,000
Term of secured loan	36 months
Unsecured loan rate of interest	9.30%
Fixed interest rate 7.3% \| Royal Bank America Leasing, L.P. \| Secured equipment financing agreement \| First installment
Commitments And Contingencies [Line Items]
Unsecured loan principal and interest payment	$ 37,000
Fixed interest rate 7.3% \| Royal Bank America Leasing, L.P. \| Secured equipment financing agreement \| Second installment
Commitments And Contingencies [Line Items]
Unsecured loan principal and interest payment	52,000
Fixed interest rate 7.3% \| Royal Bank America Leasing, L.P. \| Secured equipment financing agreement \| Third installment
Commitments And Contingencies [Line Items]
Unsecured loan principal and interest payment	61,000
Fixed interest rate 7.3% \| Royal Bank America Leasing, L.P. \| Secured equipment financing agreement \| First 12 months
Commitments And Contingencies [Line Items]
Unsecured loan principal and interest payment	3,500
Fixed interest rate 7.3% \| Royal Bank America Leasing, L.P. \| Secured equipment financing agreement \| Each of months 13-24
Commitments And Contingencies [Line Items]
Unsecured loan principal and interest payment	4,400
Fixed interest rate 7.3% \| Royal Bank America Leasing, L.P. \| Secured equipment financing agreement \| Each of months 25-36
Commitments And Contingencies [Line Items]
Unsecured loan principal and interest payment	$ 5,300
Unsecured Debt \| Fixed rate of interest 10%
Commitments And Contingencies [Line Items]
Unsecured loan					$ 1,000,000
Term of secured loan					24 months
Unsecured loan rate of interest					10.00%
Unsecured loan principal and interest payment					$ 1,000,000
Additional indebtedness limit					$ 50,000
Term of warrant					2 years
Number of warrant issued to purchase common stock					114,286
Exercise price per warrants					$ 1.75
Minimum percentage holding required by holder to retain exercising rights					more than 19.99%
Unsecured Debt \| Fixed rate of interest 10% \| Accredited investor
Commitments And Contingencies [Line Items]
Unsecured loan				$ 160,000		$ 80,000	$ 700,000
Term of secured loan				24 months		24 months	24 months
Unsecured loan rate of interest				10.00%		10.00%	10.00%
Unsecured loan principal and interest payment				$ 160,000		$ 80,000	$ 700,000
Term of warrant				2 years		2 years	2 years
Number of warrant issued to purchase common stock				18,162		9,081	79,459
Exercise price per warrants				$ 1.85		$ 1.85	$ 1.85
Minimum percentage holding required by holder to retain exercising rights				more than 4.99%		more than 4.99%	more than 4.99%
Unsecured Debt \| Fixed rate of interest 5%
Commitments And Contingencies [Line Items]
Unsecured loan								$ 500,000
Term of secured loan								24 months
Unsecured loan rate of interest								5.00%
Unsecured loan principal and interest payment								$ 500,000
Additional indebtedness limit								$ 50,000
Term of warrant								2 years
Number of warrant issued to purchase common stock								114,286
Exercise price per warrants								$ 1.75
Minimum percentage holding required by holder to retain exercising rights								more than 19.99%

XML 41 R31.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share (Details) - shares	3 Months Ended		9 Months Ended
Net Loss Per Common Share (Details) - shares	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Weighted average shares outstanding:
Total	2,792,505	1,211,754	2,713,031	1,127,950
Common stock warrants
Weighted average shares outstanding:
Total	722,988	359,714	671,516	359,714
Options
Weighted average shares outstanding:
Total	2,069,517	852,040	2,041,515	768,236

XML 42 R32.htm IDEA: XBRL DOCUMENT

Stock Option Plan - Summary of stock-based compensation activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Number of Stock Options Outstanding
Balance, January 1, 2016	1,909,911
Options granted	160,000
Options exercised
Options forfeited/canceled	394
Balance, September 30, 2016	2,069,517	1,909,911
Exercisable as of September 30, 2016	1,670,236
Weighted Average Exercise Price
Balance, January 1, 2016	$ 2.58
Options granted	2.23
Options exercised
Options forfeited/canceled	3.44
Balance, September 30, 2016	2.58	$ 2.58
Exercisable as of September 30, 2016	$ 2.60
Weighted Average Remaining Contractual Term, Options Outstanding (in years)	7 years 11 months 5 days	8 years 6 months 22 days
Weighted Average Remaining Contractual Term, Options Exercisable (in years)	7 years 8 months 27 days
Aggregate Intrinsic Value, Options Outstanding	$ 389	$ 813
Aggregate Intrinsic Value, Options Exercisable	$ 389

XML 43 R33.htm IDEA: XBRL DOCUMENT

Stock Option Plan - Weighted-average Black-Scholes fair value assumptions (Details 1)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)		5 years	5 years	5 years
Risk free interest rate			1.21%
Expected volatility		83.00%	80.40%	82.90%
Expected dividend rate		0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.50%		1.50%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.70%		1.70%

XML 44 R34.htm IDEA: XBRL DOCUMENT

Stock Option Plan - Stock-based compensation (Details 2) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 87	$ 485	$ 222	$ 549
Cost of Revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1	1	1	2
Engineering and Product Development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	16	9	34	15
Sales and Marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	27	77	70	102
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 43	$ 398	$ 117	$ 430

XML 45 R35.htm IDEA: XBRL DOCUMENT

Stock Option Plan (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended		9 Months Ended
	Jan. 31, 2016	Oct. 31, 2015	Jan. 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested awards				$ 639		$ 639
Weighted average period of unvested stock awards						2 years 3 months 7 days
Total estimated grant date fair value of options vested				$ 87	$ 485	$ 222	$ 549
Weighted average grant date fair value of options granted					$ 2.26	$ 1.43	$ 2.17
Aggregate grant date fair value					$ 1,965	$ 229	$ 2,161
2007 Key Person Stock Option Plan \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future stock-based compensation grants				0		0
Aggregate number of share reserve				407,500		407,500
2014 Stock Incentive Plan \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future stock-based compensation grants				666,121		666,121
Aggregate number of share reserve				450,000		450,000
Maximum term of stock option grants		10 years
Percentage of shares reserve increased	4.00%	4.00%	4.00%
Number of share reserve increased	204,943	1,500,000	188,640			2,343,583

XML 46 R36.htm IDEA: XBRL DOCUMENT

Stock Option Plan (Detail Textuals 1) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 18, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option granted				160,000
Stock-based compensation expense		$ 87	$ 485	$ 222	$ 549
2014 Stock Incentive Plan \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of share reserve		450,000		450,000
2014 Stock Incentive Plan \| Stock options \| Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option granted	125,000
Percentage of options vested and exercisable	25.00%
2014 Stock Incentive Plan \| Stock options \| Board of Directors \| Vesting period, Tranche one
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of option	1 year
2014 Stock Incentive Plan \| Stock options \| Board of Directors \| Vesting period, tranche two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of option	36 months
2014 Stock Incentive Plan \| Stock options \| Board of Directors \| Vesting period, tranche three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of option	4 years
2014 Stock Incentive Plan \| Stock options \| Non Employee Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of share reserve	35,000
Number of stock option granted	5,000

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 84 160 1 false 40 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://semlerscientific.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://semlerscientific.com/role/CondensedStatementsOfOperationsUnaudited Condensed Statements of Operations (Unaudited) Statements 2 false false R3.htm 003 - Statement - Condensed Balance Sheets Sheet http://semlerscientific.com/role/CondensedBalanceSheetsUnaudited Condensed Balance Sheets Statements 3 false false R4.htm 004 - Statement - Condensed Balance Sheets (Unaudited) (Parentheticals) Sheet http://semlerscientific.com/role/CondensedBalanceSheetsUnauditedParentheticals Condensed Balance Sheets (Unaudited) (Parentheticals) Statements 4 false false R5.htm 005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://semlerscientific.com/role/CondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - Basis of Presentation Sheet http://semlerscientific.com/role/BasisOfPresentation Basis of Presentation Notes 6 false false R7.htm 007 - Disclosure - Going Concern Sheet http://semlerscientific.com/role/GoingConcern Going Concern Notes 7 false false R8.htm 008 - Disclosure - Assets for Lease, net Sheet http://semlerscientific.com/role/AssetsForLeaseNet Assets for Lease, net Notes 8 false false R9.htm 009 - Disclosure - Property and Equipment, net Sheet http://semlerscientific.com/role/PropertyAndEquipmentNet Property and Equipment, net Notes 9 false false R10.htm 010 - Disclosure - Accrued Expenses Sheet http://semlerscientific.com/role/AccruedExpenses Accrued Expenses Notes 10 false false R11.htm 011 - Disclosure - Commitments and Contingencies Sheet http://semlerscientific.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 012 - Disclosure - Net Loss Per Common Share Sheet http://semlerscientific.com/role/NetLossPerCommonShare Net Loss Per Common Share Notes 12 false false R13.htm 013 - Disclosure - Stock Option Plan Sheet http://semlerscientific.com/role/StockOptionPlan Stock Option Plan Notes 13 false false R14.htm 014 - Disclosure - Subsequent Events Sheet http://semlerscientific.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 015 - Disclosure - Summary of Significant Accounting Policies and Estimates (Policies) Sheet http://semlerscientific.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies Summary of Significant Accounting Policies and Estimates (Policies) Policies 15 false false R16.htm 016 - Disclosure - Assets for lease, net (Tables) Sheet http://semlerscientific.com/role/AssetsForLeaseNetTables Assets for lease, net (Tables) Tables 16 false false R17.htm 017 - Disclosure - Property and Equipment, net (Tables) Sheet http://semlerscientific.com/role/PropertyAndEquipmentNetTables Property and Equipment, net (Tables) Tables http://semlerscientific.com/role/PropertyAndEquipmentNet 17 false false R18.htm 018 - Disclosure - Accrued Expenses (Tables) Sheet http://semlerscientific.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://semlerscientific.com/role/AccruedExpenses 18 false false R19.htm 019 - Disclosure - Commitments and Contingencies (Tables) Sheet http://semlerscientific.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://semlerscientific.com/role/CommitmentsAndContingencies 19 false false R20.htm 020 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://semlerscientific.com/role/NetLossPerCommonSharetables Net Loss Per Common Share (Tables) Tables http://semlerscientific.com/role/NetLossPerCommonShare 20 false false R21.htm 021 - Disclosure - Stock Option Plan (Tables) Sheet http://semlerscientific.com/role/StockBasedCompensationTables Stock Option Plan (Tables) Tables http://semlerscientific.com/role/StockOptionPlan 21 false false R22.htm 022 - Disclosure - Going Concern (Detail Textuals) Sheet http://semlerscientific.com/role/GoingConcernDetailTextuals Going Concern (Detail Textuals) Details http://semlerscientific.com/role/GoingConcern 22 false false R23.htm 023 - Disclosure - Assets for Lease, net - Summary of assets for lease (Details) Sheet http://semlerscientific.com/role/AssetsForLeaseNetSummaryOfAssetsForLeaseDetails Assets for Lease, net - Summary of assets for lease (Details) Details 23 false false R24.htm 024 - Disclosure - Assets for Lease, net (Detail Textuals) Sheet http://semlerscientific.com/role/AssetsForLeaseNetDetailTextuals Assets for Lease, net (Detail Textuals) Details http://semlerscientific.com/role/AssetsForLeaseNet 24 false false R25.htm 025 - Disclosure - Property and Equipment, net (Details) Sheet http://semlerscientific.com/role/PropertyAndEquipmentNetDetails Property and Equipment, net (Details) Details http://semlerscientific.com/role/PropertyAndEquipmentNetTables 25 false false R26.htm 026 - Disclosure - Property and Equipment, net (Detail Textuals) Sheet http://semlerscientific.com/role/PropertyAndEquipmentNetDetailTextuals Property and Equipment, net (Detail Textuals) Details http://semlerscientific.com/role/PropertyAndEquipmentNetTables 26 false false R27.htm 027 - Disclosure - Accrued Expenses - Summary of accrued expenses (Details) Sheet http://semlerscientific.com/role/AccruedExpensesSummaryOfAccruedExpensesDetails Accrued Expenses - Summary of accrued expenses (Details) Details 27 false false R28.htm 028 - Disclosure - Commitments and Contingencies (Details) Sheet http://semlerscientific.com/role/CommitmentsandContingenciesDetails3 Commitments and Contingencies (Details) Details http://semlerscientific.com/role/CommitmentsandContingenciesTables 28 false false R29.htm 029 - Disclosure - Commitments and Contingencies (Detail Textuals) Sheet http://semlerscientific.com/role/CommitmentsAndContingenciesDetailTextuals Commitments and Contingencies (Detail Textuals) Details http://semlerscientific.com/role/CommitmentsandContingenciesTables 29 false false R30.htm 030 - Disclosure - Commitments and Contingencies (Detail Textuals 1) Sheet http://semlerscientific.com/role/SubsequentEventsDetailTextuals Commitments and Contingencies (Detail Textuals 1) Details http://semlerscientific.com/role/CommitmentsandContingenciesTables 30 false false R31.htm 031 - Disclosure - Net Loss Per Common Share (Details) Sheet http://semlerscientific.com/role/NetLossPerCommonShareDetails Net Loss Per Common Share (Details) Details http://semlerscientific.com/role/NetLossPerCommonSharetables 31 false false R32.htm 032 - Disclosure - Stock Option Plan - Summary of stock-based compensation activity (Details) Sheet http://semlerscientific.com/role/StockBasedCompensationSummaryOfStockBasedCompensationActivityDetails1 Stock Option Plan - Summary of stock-based compensation activity (Details) Details 32 false false R33.htm 033 - Disclosure - Stock Option Plan - Weighted-average Black-Scholes fair value assumptions (Details 1) Sheet http://semlerscientific.com/role/StockBasedCompensationWeightedAverageBlackScholesFairValueAssumptionsDetails Stock Option Plan - Weighted-average Black-Scholes fair value assumptions (Details 1) Details 33 false false R34.htm 034 - Disclosure - Stock Option Plan - Stock-based compensation (Details 2) Sheet http://semlerscientific.com/role/StockOptionPlanDetails2 Stock Option Plan - Stock-based compensation (Details 2) Details 34 false false R35.htm 035 - Disclosure - Stock Option Plan (Detail Textuals) Sheet http://semlerscientific.com/role/Stockbasedcompensationdetailtextuals Stock Option Plan (Detail Textuals) Details http://semlerscientific.com/role/StockBasedCompensationTables 35 false false R36.htm 036 - Disclosure - Stock Option Plan (Detail Textuals 1) Sheet http://semlerscientific.com/role/StockBasedCompensationDetailTextuals1 Stock Option Plan (Detail Textuals 1) Details http://semlerscientific.com/role/StockBasedCompensationTables 36 false false All Reports Book All Reports smlr-20160930.xml smlr-20160930.xsd smlr-20160930_cal.xml smlr-20160930_def.xml smlr-20160930_lab.xml smlr-20160930_pre.xml true true ZIP 53 0001571049-16-019407-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001571049-16-019407-xbrl.zip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end